{
    "PMC5564609_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "delayed gastric emptying",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[15, 0.02]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Delayed gastric emptying",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[15, 0.02]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "delayed gastric emptying",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[32, 0.02]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Delayed gastric emptying",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[32, 0.02]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "bleeding",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[6, 0.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Bleeding",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[6, 0.5]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "bleeding",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[4, 0.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Bleeding",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[4, 0.5]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatic fistula",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[39, 0.52]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatic fistula",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[39, 0.52]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatic fistula",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[36, 0.52]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatic fistula",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test",
                        "Grade": "A"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[8, 0.52]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatic fistula",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[36, 0.52]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatic fistula",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test",
                        "Grade": "A"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[6, 0.52]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatic fistula",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[36, 0.52]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatic fistula",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test",
                        "Grade": "B"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[10, 0.52]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatic fistula",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[36, 0.52]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatic fistula",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test",
                        "Grade": "B"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[6, 0.52]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatic fistula",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[36, 0.52]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatic fistula",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test",
                        "Grade": "C"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[21, 0.52]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatic fistula",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[36, 0.52]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatic fistula",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test",
                        "Grade": "C"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[24, 0.52]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatic fistula",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[36, 0.52]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatic fistula",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[36, 0.52]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatic fistula",
                        "grade": "A",
                        "group": "ERAS",
                        "sample size": "76"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatic fistula",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test",
                        "Grade": "A"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[8, 0.52]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatic fistula",
                        "grade": "A",
                        "group": "Conventional",
                        "sample size": "83"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatic fistula",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test",
                        "Grade": "A"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[6, 0.52]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatic fistula",
                        "grade": "B",
                        "group": "ERAS",
                        "sample size": "76"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[10]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatic fistula",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test",
                        "Grade": "B"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[10, 0.52]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatic fistula",
                        "grade": "B",
                        "group": "Conventional",
                        "sample size": "83"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatic fistula",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test",
                        "Grade": "B"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[6, 0.52]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatic fistula",
                        "grade": "C",
                        "group": "ERAS",
                        "sample size": "76"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[21]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatic fistula",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test",
                        "Grade": "C"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[21, 0.52]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatic fistula",
                        "grade": "C",
                        "group": "Conventional",
                        "sample size": "83"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[24]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatic fistula",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test",
                        "Grade": "C"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[24, 0.52]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "biliary fistula",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[2, 0.47]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Biliary fistula",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[2, 0.47]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "biliary fistula",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[0, 0.47]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Biliary fistula",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[0, 0.47]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "wound infection",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[5, 0.66]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Wound infection",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[5, 0.66]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "wound infection",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[3, 0.66]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Wound infection",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[3, 0.66]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pulmonary complication",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[2, 0.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pulmonary complication",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[2, 0.1]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pulmonary complication",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[4, 0.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pulmonary complication",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[4, 0.1]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "skin orifice infection",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[1, 0.012]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Skin orifice infection",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 0.012]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "skin orifice infection",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[6, 0.012]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Skin orifice infection",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[6, 0.012]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatitis",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[2, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatitis",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Sepsis",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Sepsis",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[0, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Re-laparotomy",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[3, 0.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Re-laparotomy",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 0.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Readmission (in 30 days)",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Readmission (in 30 days)",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Abdominal abscess",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[0, /]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatitis",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[2, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatitis",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Sepsis",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Sepsis",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[0, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Re-laparotomy",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[3, 0.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Re-laparotomy",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 0.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Readmission (in 30 days)",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Readmission (in 30 days)",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "abdominal abscess",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Abdominal abscess",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[0, /]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatitis",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[2, 1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatitis",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[2, 1]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "pancreatitis",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[1, 1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Pancreatitis",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "sepsis",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[1, 1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Sepsis",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "sepsis",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[0, 1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Sepsis",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[0, 1]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "re-laparotomy",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[3, 0.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Re-laparotomy",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[3, 0.6]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "re-laparotomy",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[1, 0.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Re-laparotomy",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 0.6]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "outcome": "mortality",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Readmission (in 30 days)",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "outcome": "mortality",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Readmission (in 30 days)",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "outcome": "mortality",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Mortality",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[0, /]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "outcome": "mortality",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Readmission (in 30 days)",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "outcome": "mortality",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Readmission (in 30 days)",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "outcome": "mortality",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Mortality",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[0, /]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "readmission",
                        "timeframe": "in 30 days",
                        "group": "ERAS",
                        "sample size": "76",
                        "comparison": "Conventional",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[1, 1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Readmission (in 30 days)",
                        "Group": "ERAS",
                        "Sample size": "76",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "complication": "readmission",
                        "timeframe": "in 30 days",
                        "group": "Conventional",
                        "sample size": "83",
                        "comparison": "ERAS",
                        "statistical test": "Fisher exact test"
                    },
                    "measures": "[incidence, P]",
                    "outcomes": "[1, 1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Post-operative complication": "Readmission (in 30 days)",
                        "Group": "Conventional",
                        "Sample size": "83",
                        "Statistical test": "Fisher exact test"
                    },
                    "measures": "[Incidence, p-value]",
                    "outcomes": "[1, 1]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 32,
        "total_ground_truth_claims": 32,
        "number_of_matches": 32
    },
    "PMC5762325_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "correlation analysis",
                        "tissue type": "tumor tissue",
                        "cancer type": "pancreatic cancer",
                        "protein 1": "E-cadherin",
                        "protein 2": "STYK1",
                        "E-cadherin expression": "low",
                        "STYK1 expression": "low"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Tumor tissue sample": "E-cadherin Low",
                        "STYK1 Low": "9",
                        "STYK1 High": "23",
                        "Cancer type": "pancreatic cancer",
                        "Analysis type": "Correlation analysis"
                    },
                    "measures": "[Correlation coefficient, p-value]",
                    "outcomes": "[-0.420, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "correlation analysis",
                        "tissue type": "tumor tissue",
                        "cancer type": "pancreatic cancer",
                        "protein 1": "E-cadherin",
                        "protein 2": "STYK1",
                        "E-cadherin expression": "low",
                        "STYK1 expression": "low"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Tumor tissue sample": "E-cadherin High",
                        "STYK1 Low": "34",
                        "STYK1 High": "14",
                        "Cancer type": "pancreatic cancer",
                        "Analysis type": "Correlation analysis"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "correlation analysis",
                        "tissue type": "tumor tissue",
                        "cancer type": "pancreatic cancer",
                        "protein 1": "E-cadherin",
                        "protein 2": "STYK1",
                        "E-cadherin expression": "low",
                        "STYK1 expression": "high"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Tumor tissue sample": "E-cadherin Low",
                        "STYK1 Low": "9",
                        "STYK1 High": "23",
                        "Cancer type": "pancreatic cancer",
                        "Analysis type": "Correlation analysis"
                    },
                    "measures": "[Correlation coefficient, p-value]",
                    "outcomes": "[-0.420, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "correlation analysis",
                        "tissue type": "tumor tissue",
                        "cancer type": "pancreatic cancer",
                        "protein 1": "E-cadherin",
                        "protein 2": "STYK1",
                        "E-cadherin expression": "low",
                        "STYK1 expression": "high"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Tumor tissue sample": "E-cadherin High",
                        "STYK1 Low": "34",
                        "STYK1 High": "14",
                        "Cancer type": "pancreatic cancer",
                        "Analysis type": "Correlation analysis"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "correlation analysis",
                        "tissue type": "tumor tissue",
                        "cancer type": "pancreatic cancer",
                        "protein 1": "E-cadherin",
                        "protein 2": "STYK1",
                        "E-cadherin expression": "high",
                        "STYK1 expression": "low"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Tumor tissue sample": "E-cadherin Low",
                        "STYK1 Low": "9",
                        "STYK1 High": "23",
                        "Cancer type": "pancreatic cancer",
                        "Analysis type": "Correlation analysis"
                    },
                    "measures": "[Correlation coefficient, p-value]",
                    "outcomes": "[-0.420, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "correlation analysis",
                        "tissue type": "tumor tissue",
                        "cancer type": "pancreatic cancer",
                        "protein 1": "E-cadherin",
                        "protein 2": "STYK1",
                        "E-cadherin expression": "high",
                        "STYK1 expression": "low"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Tumor tissue sample": "E-cadherin High",
                        "STYK1 Low": "34",
                        "STYK1 High": "14",
                        "Cancer type": "pancreatic cancer",
                        "Analysis type": "Correlation analysis"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "correlation analysis",
                        "tissue type": "tumor tissue",
                        "cancer type": "pancreatic cancer",
                        "protein 1": "E-cadherin",
                        "protein 2": "STYK1",
                        "E-cadherin expression": "high",
                        "STYK1 expression": "high"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Tumor tissue sample": "E-cadherin Low",
                        "STYK1 Low": "9",
                        "STYK1 High": "23",
                        "Cancer type": "pancreatic cancer",
                        "Analysis type": "Correlation analysis"
                    },
                    "measures": "[Correlation coefficient, p-value]",
                    "outcomes": "[-0.420, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "correlation analysis",
                        "tissue type": "tumor tissue",
                        "cancer type": "pancreatic cancer",
                        "protein 1": "E-cadherin",
                        "protein 2": "STYK1"
                    },
                    "measures": "[correlation coefficient, P-value]",
                    "outcomes": "[-0.420, <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Tumor tissue sample": "E-cadherin Low",
                        "STYK1 Low": "9",
                        "STYK1 High": "23",
                        "Cancer type": "pancreatic cancer",
                        "Analysis type": "Correlation analysis"
                    },
                    "measures": "[Correlation coefficient, p-value]",
                    "outcomes": "[-0.420, <0.001]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 5,
        "total_ground_truth_claims": 2,
        "number_of_matches": 2
    },
    "PMC3798558_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "XRCC1",
                        "analysis": "haplotype analysis",
                        "haplotype": "1",
                        "SNP1": "C",
                        "SNP2": "G",
                        "SNP1_rs": "rs1799782",
                        "SNP2_rs": "rs25487",
                        "haplotype_frequency_overall": "0.439",
                        "haplotype_frequency_cases": "0.433",
                        "haplotype_frequency_controls": "0.442",
                        "adjusted_OR": "1.00",
                        "reference": "ref.",
                        "sample_size_cases": "185",
                        "sample_size_controls": "1465",
                        "adjustment_factors": "age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, family history of PC",
                        "statistical_method": "Haplotype-effects logistic regression for case-control data"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "haplotype analysis for XRCC1",
                        "haplotype": "CG",
                        "SNP 1": "rs1799782",
                        "SNP 2": "rs25487",
                        "haplotype frequency (overall)": "0.439",
                        "haplotype frequency (cases)": "0.433",
                        "haplotype frequency (controls)": "0.442",
                        "method": "haplotype-effects logistic regression for case-control data",
                        "mutivariable adjustment": "age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC",
                        "cases": "185",
                        "controls": "1465"
                    },
                    "measures": "[Adjusted OR]",
                    "outcomes": "[1.00 (ref.)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "XRCC1",
                        "analysis": "haplotype analysis",
                        "haplotype": "2",
                        "SNP1": "C",
                        "SNP2": "A",
                        "SNP1_rs": "rs1799782",
                        "SNP2_rs": "rs25487",
                        "haplotype_frequency_overall": "0.240",
                        "haplotype_frequency_cases": "0.274",
                        "haplotype_frequency_controls": "0.239",
                        "adjusted_OR": "1.32",
                        "CI": "1.01-1.71",
                        "p_value": "0.042",
                        "sample_size_cases": "185",
                        "sample_size_controls": "1465",
                        "adjustment_factors": "age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, family history of PC",
                        "statistical_method": "Haplotype-effects logistic regression for case-control data"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "haplotype analysis for XRCC1",
                        "haplotype": "CA",
                        "SNP 1": "rs1799782",
                        "SNP 2": "rs25487",
                        "haplotype frequency (overall)": "0.240",
                        "haplotype frequency (cases)": "0.274",
                        "haplotype frequency (controls)": "0.239",
                        "method": "haplotype-effects logistic regression for case-control data",
                        "mutivariable adjustment": "age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC",
                        "cases": "185",
                        "controls": "1465",
                        "R-squared value between rs1799782 and rs25487": "0.15"
                    },
                    "measures": "[Adjusted OR, 95% CI, P-value]",
                    "outcomes": "[1.32, 1.01-1.71, 0.042]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "XRCC1",
                        "analysis": "haplotype analysis",
                        "haplotype": "3",
                        "SNP1": "T",
                        "SNP2": "G",
                        "SNP1_rs": "rs1799782",
                        "SNP2_rs": "rs25487",
                        "haplotype_frequency_overall": "0.319",
                        "haplotype_frequency_cases": "0.292",
                        "haplotype_frequency_controls": "0.318",
                        "adjusted_OR": "1.05",
                        "CI": "0.81-1.36",
                        "p_value": "0.691",
                        "sample_size_cases": "185",
                        "sample_size_controls": "1465",
                        "adjustment_factors": "age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, family history of PC",
                        "statistical_method": "Haplotype-effects logistic regression for case-control data"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "haplotype analysis for XRCC1",
                        "haplotype": "TG",
                        "SNP 1": "rs1799782",
                        "SNP 2": "rs25487",
                        "haplotype frequency (overall)": "0.319",
                        "haplotype frequency (cases)": "0.292",
                        "haplotype frequency (controls)": "0.318",
                        "method": "haplotype-effects logistic regression for case-control data",
                        "mutivariable adjustment": "age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC",
                        "cases": "185",
                        "controls": "1465",
                        "R-squared value between rs1799782 and rs25487": "0.15"
                    },
                    "measures": "[Adjusted OR, CI, P-value]",
                    "outcomes": "[1.05, 0.81-1.36, 0.691]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "gene": "XRCC1",
                        "analysis": "haplotype analysis",
                        "haplotype": "4",
                        "SNP1": "T",
                        "SNP2": "A",
                        "SNP1_rs": "rs1799782",
                        "SNP2_rs": "rs25487",
                        "haplotype_frequency_overall": "0.002",
                        "haplotype_frequency_cases": "<0.001",
                        "haplotype_frequency_controls": "0.002",
                        "adjusted_OR": "N.E.",
                        "p_value": "N.E.",
                        "sample_size_cases": "185",
                        "sample_size_controls": "1465",
                        "adjustment_factors": "age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, family history of PC",
                        "statistical_method": "Haplotype-effects logistic regression for case-control data"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "haplotype analysis for XRCC1",
                        "haplotype": "TA",
                        "SNP 1": "rs1799782",
                        "SNP 2": "rs25487",
                        "haplotype frequency (overall)": "0.002",
                        "haplotype frequency (cases)": "<0.001",
                        "haplotype frequency (controls)": "0.002",
                        "method": "haplotype-effects logistic regression for case-control data",
                        "mutivariable adjustment": "age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC",
                        "cases": "185",
                        "controls": "1465",
                        "R-squared value between rs1799782 and rs25487": "0.15"
                    },
                    "measures": "[Adjusted OR, CI, P-value]",
                    "outcomes": "[N.E., N.E., N.E.]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 5,
        "total_ground_truth_claims": 4,
        "number_of_matches": 4
    },
    "PMC4423458_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Fibrinogen beta chain isoform 1 pre-pro-protein",
                        "accession": "70906435",
                        "molecular weight": "56 kDa",
                        "average spectral count cancer": "138.8",
                        "average spectral count control": "52.1",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[2.2, 0.01481]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Fibrinogen beta chain isoform 1 pre-pro-protein",
                        "accession": "70906435",
                        "Molecural weight (MW) (kDa)": "56",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[138.8, 52.1, 2.2, 0.01481]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "C4b-binding protein alpha chain precursor",
                        "accession": "4502503",
                        "molecular weight": "67 kDa",
                        "average spectral count cancer": "37.3",
                        "average spectral count control": "11.5",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[2.3, 0.04311]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "C4b-binding protein alpha chain precursor",
                        "accession": "4502503",
                        "Molecural weight (MW) (kDa)": "67",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[37.3, 11.5, 2.3, 0.04311]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Serum albumin pre-pro-protein",
                        "accession": "4502027",
                        "molecular weight": "69 kDa",
                        "average spectral count cancer": "986.0",
                        "average spectral count control": "332.8",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[2.4, 0.00006]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Serum albumin pre-pro-protein",
                        "accession": "4502027",
                        "Molecural weight (MW) (kDa)": "69",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[986.0, 332.8, 2.4, 0.00006]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Vitamin D-binding protein isoform 1 precursor",
                        "accession": "32483410",
                        "molecular weight": "53 kDa",
                        "average spectral count cancer": "51.9",
                        "average spectral count control": "19.2",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[2.4, 0.03919]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Vitamin D-binding protein isoform 1 precursor",
                        "accession": "32483410",
                        "Molecural weight (MW) (kDa)": "53",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[51.9, 19.2, 2.4, 0.03919]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Kininogen-1 isoform 2 precursor",
                        "accession": "4504893",
                        "molecular weight": "48 kDa",
                        "average spectral count cancer": "21.3",
                        "average spectral count control": "5.5",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[3.8, 0.01109]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Kininogen-1 isoform 2 precursor",
                        "accession": "4504893",
                        "Molecural weight (MW) (kDa)": "48",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[21.3, 5.5, 3.8, 0.01109]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Alpha-2-macroglobulin precursor",
                        "accession": "66932947",
                        "molecular weight": "163 kDa",
                        "average spectral count cancer": "127.9",
                        "average spectral count control": "29.3",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[3.9, 0.00618]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Alpha-2-macroglobulin precursor",
                        "accession": "66932947",
                        "Molecural weight (MW) (kDa)": "163",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[127.9, 29.3, 3.9, 0.00618]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Haptoglobin isoform 1 pre-pro-protein",
                        "accession": "4826762",
                        "molecular weight": "45 kDa",
                        "average spectral count cancer": "83.8",
                        "average spectral count control": "18.0",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[4.2, 0.00024]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Haptoglobin isoform 1 pre-pro-protein",
                        "accession": "4826762",
                        "Molecural weight (MW) (kDa)": "45",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[83.8, 18.0, 4.2, 0.00024]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Fibrinogen gamma chain isoform gamma-B precursor",
                        "accession": "70906439",
                        "molecular weight": "52 kDa",
                        "average spectral count cancer": "89.3",
                        "average spectral count control": "17.3",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[4.3, 0.00133]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Fibrinogen gamma chain isoform gamma-B precursor",
                        "accession": "70906439",
                        "Molecural weight (MW) (kDa)": "52",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[89.3, 17.3, 4.3, 0.00133]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Complement C3 precursor",
                        "accession": "115298678",
                        "molecular weight": "187 kDa",
                        "average spectral count cancer": "174.7",
                        "average spectral count control": "35.6",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[4.3, 0.00612]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Complement C3 precursor",
                        "accession": "115298678",
                        "Molecural weight (MW) (kDa)": "187",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[174.7, 35.6, 4.3, 0.00612]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Myeloperoxidase precursor",
                        "accession": "4557759",
                        "molecular weight": "84 kDa",
                        "average spectral count cancer": "70.2",
                        "average spectral count control": "11.0",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[5.3, 0.02501]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Myeloperoxidase precursor",
                        "accession": "4557759",
                        "Molecural weight (MW) (kDa)": "84",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[70.2, 11.0, 5.3, 0.02501]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Apolipoprotein A-I pre-pro-protein",
                        "accession": "4557321",
                        "molecular weight": "31 kDa",
                        "average spectral count cancer": "29.8",
                        "average spectral count control": "5.9",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[5.7, 0.02170]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Apolipoprotein A-I pre-pro-protein",
                        "accession": "4557321",
                        "Molecural weight (MW) (kDa)": "31",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[29.8, 5.9, 5.7, 0.02170]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Fibrinogen alpha chain isoform alpha-E pre-pro-protein",
                        "accession": "4503689",
                        "molecular weight": "95 kDa",
                        "average spectral count cancer": "63.3",
                        "average spectral count control": "9.3",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[6.4, 0.00031]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Fibrinogen alpha chain isoform alpha-E pre-pro-protein",
                        "accession": "4503689",
                        "Molecural weight (MW) (kDa)": "95",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[63.3, 9.3, 6.4, 0.00031]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Alpha-2-HS-glycoprotein pre-pro-protein",
                        "accession": "156523970",
                        "molecular weight": "39 kDa",
                        "average spectral count cancer": "7.3",
                        "average spectral count control": "1.1",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[6.5, 0.00173]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Alpha-2-HS-glycoprotein pre-pro-protein",
                        "accession": "156523970",
                        "Molecural weight (MW) (kDa)": "39",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[7.3, 1.1, 6.5, 0.00173]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Ceruloplasmin precursor",
                        "accession": "4557485",
                        "molecular weight": "122 kDa",
                        "average spectral count cancer": "47.3",
                        "average spectral count control": "5.6",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[7.5, 0.00114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Ceruloplasmin precursor",
                        "accession": "4557485",
                        "Molecural weight (MW) (kDa)": "122",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[47.3, 5.6, 7.5, 0.00114]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "PREDICTED: complement C4-A isoform 1",
                        "accession": "341916194",
                        "molecular weight": "193 kDa",
                        "average spectral count cancer": "32.1",
                        "average spectral count control": "4.5",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[7.7, 0.01791]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "PREDICTED: complement C4-A isoform 1",
                        "accession": "341916194",
                        "Molecural weight (MW) (kDa)": "193",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[32.1, 4.5, 7.7, 0.01791]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Alpha-1B-glycoprotein precursor",
                        "accession": "21071030",
                        "molecular weight": "54 kDa",
                        "average spectral count cancer": "10.9",
                        "average spectral count control": "1.2",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[8.3, 0.00468]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Alpha-1B-glycoprotein precursor",
                        "accession": "21071030",
                        "Molecural weight (MW) (kDa)": "54",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[10.9, 1.2, 8.3, 0.00468]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor",
                        "accession": "31542984",
                        "molecular weight": "103 kDa",
                        "average spectral count cancer": "5.5",
                        "average spectral count control": "0.2",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[35.4, 0.00484]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor",
                        "accession": "31542984",
                        "Molecural weight (MW) (kDa)": "103",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[5.5, 0.2, 35.4, 0.00484]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "protein": "Apolipoprotein B-100 precursor",
                        "accession": "105990532",
                        "molecular weight": "516 kDa",
                        "average spectral count cancer": "49.3",
                        "average spectral count control": "1.0",
                        "comparison": "cancer vs control",
                        "control": "primary sclerosing cholangitis and benign strictures"
                    },
                    "measures": "[normalized spectral abundance factor ratio, P-value (t-test)]",
                    "outcomes": "[55.7, 0.02595]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                        "protein": "Apolipoprotein B-100 precursor",
                        "accession": "105990532",
                        "Molecural weight (MW) (kDa)": "516",
                        "statistical test": "t-test"
                    },
                    "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                    "outcomes": "[49.3, 1.0, 55.7, 0.02595]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 18,
        "total_ground_truth_claims": 18,
        "number_of_matches": 18
    },
    "PMC5589562_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "TAS cells",
                        "comparison to": "PC cells",
                        "miRNA probe ID": "hsa-miR-145-5p",
                        "accession number": "MIMAT0000437"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[8980.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-145-5p",
                        "Accession no.": "MIMAT0000437",
                        "Cell type": "TAS cells",
                        "Expression level": "highly expressed",
                        "Rank": "1"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['8980.05']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "TAS cells",
                        "comparison to": "PC cells",
                        "miRNA probe ID": "hsa-miR-199a-5p",
                        "accession number": "MIMAT0000231"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[1563.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-199a-5p",
                        "Accession no.": "MIMAT0000231",
                        "Cell type": "TAS cells",
                        "Expression level": "highly expressed",
                        "Rank": "2"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['1563.68']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "TAS cells",
                        "comparison to": "PC cells",
                        "miRNA probe ID": "hsa-miR-199b-5p",
                        "accession number": "MIMAT0000263"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[296.31]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-199b-5p",
                        "Accession no.": "MIMAT0000263",
                        "Cell type": "TAS cells",
                        "Expression level": "highly expressed",
                        "Rank": "3"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['296.31']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "TAS cells",
                        "comparison to": "PC cells",
                        "miRNA probe ID": "hsa-miR-136-5p",
                        "accession number": "MIMAT0000448"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[228.24]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-136-5p",
                        "Accession no.": "MIMAT0000448",
                        "Cell type": "TAS cells",
                        "Expression level": "highly expressed",
                        "Rank": "4"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['228.24']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "TAS cells",
                        "comparison to": "PC cells",
                        "miRNA probe ID": "hsa-miR-137",
                        "accession number": "MIMAT0000429"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[227.70]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-137",
                        "Accession no.": "MIMAT0000429",
                        "Cell type": "TAS cells",
                        "Expression level": "highly expressed",
                        "Rank": "5"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['227.70']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "TAS cells",
                        "comparison to": "PC cells",
                        "miRNA probe ID": "hsa-miR-139-5p",
                        "accession number": "MIMAT0000250"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[216.83]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-139-5p",
                        "Accession no.": "MIMAT0000250",
                        "Cell type": "TAS cells",
                        "Expression level": "highly expressed",
                        "Rank": "6"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['216.83']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "TAS cells",
                        "comparison to": "PC cells",
                        "miRNA probe ID": "hsa-miR-127-3p",
                        "accession number": "MIMAT0000446"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[159.72]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-127-3p",
                        "Accession no.": "MIMAT0000446",
                        "Cell type": "TAS cells",
                        "Expression level": "highly expressed",
                        "Rank": "7"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['159.72']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "TAS cells",
                        "comparison to": "PC cells",
                        "miRNA probe ID": "hsa-miR-337-5p",
                        "accession number": "MIMAT0004695"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[148.57]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-337-5p",
                        "Accession no.": "MIMAT0004695",
                        "Cell type": "TAS cells",
                        "Expression level": "highly expressed",
                        "Rank": "8"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['148.57']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "TAS cells",
                        "comparison to": "PC cells",
                        "miRNA probe ID": "hsa-miR-139-3p",
                        "accession number": "MIMAT0004552"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[146.36]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-139-3p",
                        "Accession no.": "MIMAT0004552",
                        "Cell type": "TAS cells",
                        "Expression level": "highly expressed",
                        "Rank": "9"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['146.36']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "TAS cells",
                        "comparison to": "PC cells",
                        "miRNA probe ID": "hsa-miR-487b",
                        "accession number": "MIMAT0003180"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[118.72]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-487b",
                        "Accession no.": "MIMAT0003180",
                        "Cell type": "TAS cells",
                        "Expression level": "highly expressed",
                        "Rank": "10"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['118.72']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "TAS cells",
                        "comparison to": "PC cells",
                        "miRNA probe ID": "hsa-miR-199a-3p+hsa-miR-199b-3p",
                        "accession number": "MIMAT0000232"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[107.49]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-199a-3p+hsa-miR-199b-3p",
                        "Accession no.": "MIMAT0000232",
                        "Cell type": "TAS cells",
                        "Expression level": "highly expressed",
                        "Rank": "11"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['107.49']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "TAS cells",
                        "comparison to": "PC cells",
                        "miRNA probe ID": "hsa-miR-1233",
                        "accession number": "MIMAT0005588"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[66.04]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-1233",
                        "Accession no.": "MIMAT0005588",
                        "Cell type": "TAS cells",
                        "Expression level": "highly expressed",
                        "Rank": "12"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['66.04']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "TAS cells",
                        "comparison to": "PC cells",
                        "miRNA probe ID": "hsa-miR-379-5p",
                        "accession number": "MIMAT0000733"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[62.89]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-379-5p",
                        "Accession no.": "MIMAT0000733",
                        "Cell type": "TAS cells",
                        "Expression level": "highly expressed",
                        "Rank": "13"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['62.89']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "TAS cells",
                        "comparison to": "PC cells",
                        "miRNA probe ID": "hsa-miR-660-5p",
                        "accession number": "MIMAT0003338"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[62.50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-660-5p",
                        "Accession no.": "MIMAT0003338",
                        "Cell type": "TAS cells",
                        "Expression level": "highly expressed",
                        "Rank": "14"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['62.50']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "TAS cells",
                        "comparison to": "PC cells",
                        "miRNA probe ID": "hsa-miR-335-5p",
                        "accession number": "MIMAT0000765"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[60.53]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-335-5p",
                        "Accession no.": "MIMAT0000765",
                        "Cell type": "TAS cells",
                        "Expression level": "highly expressed",
                        "Rank": "15"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['60.53']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "PC cells",
                        "comparison to": "TAS cells",
                        "miRNA probe ID": "hsa-miR-205-5p",
                        "accession number": "MIMAT0000266"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[23077.19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-205-5p",
                        "Accession no.": "MIMAT0000266",
                        "Cell type": "PC cells",
                        "Expression level": "highly expressed",
                        "Rank": "1"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['23077.19']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "PC cells",
                        "comparison to": "TAS cells",
                        "miRNA probe ID": "hsa-miR-200c-3p",
                        "accession number": "MIMAT0000617"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[5968.64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-200c-3p",
                        "Accession no.": "MIMAT0000617",
                        "Cell type": "PC cells",
                        "Expression level": "highly expressed",
                        "Rank": "2"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['5968.64']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "PC cells",
                        "comparison to": "TAS cells",
                        "miRNA probe ID": "hsa-miR-200b-3p",
                        "accession number": "MIMAT0000318"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[467.15]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-200b-3p",
                        "Accession no.": "MIMAT0000318",
                        "Cell type": "PC cells",
                        "Expression level": "highly expressed",
                        "Rank": "3"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['467.15']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "PC cells",
                        "comparison to": "TAS cells",
                        "miRNA probe ID": "hsa-miR-429",
                        "accession number": "MIMAT0001536"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[171.07]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-429",
                        "Accession no.": "MIMAT0001536",
                        "Cell type": "PC cells",
                        "Expression level": "highly expressed",
                        "Rank": "4"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['171.07']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "PC cells",
                        "comparison to": "TAS cells",
                        "miRNA probe ID": "hsa-miR-196b-5p",
                        "accession number": "MIMAT0001080"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[116.42]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-196b-5p",
                        "Accession no.": "MIMAT0001080",
                        "Cell type": "PC cells",
                        "Expression level": "highly expressed",
                        "Rank": "5"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['116.42']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "PC cells",
                        "comparison to": "TAS cells",
                        "miRNA probe ID": "hsa-miR-582-5p",
                        "accession number": "MIMAT0003247"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[99.53]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-582-5p",
                        "Accession no.": "MIMAT0003247",
                        "Cell type": "PC cells",
                        "Expression level": "highly expressed",
                        "Rank": "6"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['99.53']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "PC cells",
                        "comparison to": "TAS cells",
                        "miRNA probe ID": "hsa-miR-135b-5p",
                        "accession number": "MIMAT0000758"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[87.82]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-135b-5p",
                        "Accession no.": "MIMAT0000758",
                        "Cell type": "PC cells",
                        "Expression level": "highly expressed",
                        "Rank": "7"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['87.82']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "PC cells",
                        "comparison to": "TAS cells",
                        "miRNA probe ID": "hsa-miR-182-5p",
                        "accession number": "MIMAT0000259"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[55.81]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-182-5p",
                        "Accession no.": "MIMAT0000259",
                        "Cell type": "PC cells",
                        "Expression level": "highly expressed",
                        "Rank": "8"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['55.81']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "PC cells",
                        "comparison to": "TAS cells",
                        "miRNA probe ID": "hsa-miR-96-5p",
                        "accession number": "MIMAT0000095"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[53.82]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-96-5p",
                        "Accession no.": "MIMAT0000095",
                        "Cell type": "PC cells",
                        "Expression level": "highly expressed",
                        "Rank": "9"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['53.82']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "PC cells",
                        "comparison to": "TAS cells",
                        "miRNA probe ID": "hsa-miR-200a-3p",
                        "accession number": "MIMAT0000682"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[44.88]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-200a-3p",
                        "Accession no.": "MIMAT0000682",
                        "Cell type": "PC cells",
                        "Expression level": "highly expressed",
                        "Rank": "10"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['44.88']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "PC cells",
                        "comparison to": "TAS cells",
                        "miRNA probe ID": "hsa-miR-4284",
                        "accession number": "MIMAT0016915"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[41.90]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-4284",
                        "Accession no.": "MIMAT0016915",
                        "Cell type": "PC cells",
                        "Expression level": "highly expressed",
                        "Rank": "11"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['41.90']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "PC cells",
                        "comparison to": "TAS cells",
                        "miRNA probe ID": "hsa-miR-345-5p",
                        "accession number": "MIMAT0000772"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[27.99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-345-5p",
                        "Accession no.": "MIMAT0000772",
                        "Cell type": "PC cells",
                        "Expression level": "highly expressed",
                        "Rank": "12"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['27.99']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "PC cells",
                        "comparison to": "TAS cells",
                        "miRNA probe ID": "hsa-miR-378g",
                        "accession number": "MIMAT0018937"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[25.01]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-378g",
                        "Accession no.": "MIMAT0018937",
                        "Cell type": "PC cells",
                        "Expression level": "highly expressed",
                        "Rank": "13"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['25.01']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "PC cells",
                        "comparison to": "TAS cells",
                        "miRNA probe ID": "hsa-miR-203",
                        "accession number": "MIMAT0000264"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[22.43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-203",
                        "Accession no.": "MIMAT0000264",
                        "Cell type": "PC cells",
                        "Expression level": "highly expressed",
                        "Rank": "14"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['22.43']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "miRNA expression comparison",
                        "cell type": "PC cells",
                        "comparison to": "TAS cells",
                        "miRNA probe ID": "hsa-miR-141-3p",
                        "accession number": "MIMAT0000432"
                    },
                    "measures": "[expression ratio]",
                    "outcomes": "[21.69]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "miRNA probe ID": "hsa-miR-141-3p",
                        "Accession no.": "MIMAT0000432",
                        "Cell type": "PC cells",
                        "Expression level": "highly expressed",
                        "Rank": "15"
                    },
                    "measures": "['Expression ratio']",
                    "outcomes": "['21.69']"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 30,
        "total_ground_truth_claims": 30,
        "number_of_matches": 30
    },
    "PMC4190529_6": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine",
                        "control": "5-fluorouracil",
                        "phase": "3",
                        "cancer type": "pancreatic cancer"
                    },
                    "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                    "outcomes": "[5.7, 4.2, 18, 2, 1996]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine",
                        "Control": "5-fluorouracil",
                        "Phase": "3",
                        "Side Effects": "more favorable than 5-fluorouracil",
                        "FDA Approval": "1996",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control]",
                    "outcomes": "['5.7', '4.2']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine",
                        "control": "5-fluorouracil",
                        "phase": "3",
                        "cancer type": "pancreatic cancer",
                        "side effects": "more favorable than 5-fluorouracil"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine",
                        "Control": "5-fluorouracil",
                        "Phase": "3",
                        "Side Effects": "more favorable than 5-fluorouracil",
                        "FDA Approval": "1996",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                    "outcomes": "['18%', '2%']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "control": "gemcitabine",
                        "phase": "3",
                        "cancer type": "pancreatic cancer"
                    },
                    "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                    "outcomes": "[6.4, 6, 24, 19, 2005]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2005",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['6.4', '6']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "control": "gemcitabine",
                        "phase": "3",
                        "cancer type": "pancreatic cancer"
                    },
                    "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                    "outcomes": "[6.4, 6, 24, 19, 2005]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2005",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                    "outcomes": "['24%', '19%']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "control": "gemcitabine",
                        "phase": "3",
                        "cancer type": "pancreatic cancer"
                    },
                    "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                    "outcomes": "[6.4, 6, 24, 19, 2005]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2013",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['8.5', '6.7']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "control": "gemcitabine",
                        "phase": "3",
                        "cancer type": "pancreatic cancer"
                    },
                    "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                    "outcomes": "[6.4, 6, 24, 19, 2005]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2013",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                    "outcomes": "['35%', '22%']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "control": "gemcitabine",
                        "phase": "3",
                        "cancer type": "pancreatic cancer"
                    },
                    "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                    "outcomes": "[6.4, 6, 24, 19, 2005]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "FOLFIRINOX",
                        "Control": "gemcitabine",
                        "Phase": "2/3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "n/a",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['11.1', '6.8']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "control": "gemcitabine",
                        "phase": "3",
                        "cancer type": "pancreatic cancer"
                    },
                    "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                    "outcomes": "[6.4, 6, 24, 19, 2005]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "FOLFIRINOX",
                        "Control": "gemcitabine",
                        "Phase": "2/3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "n/a",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                    "outcomes": "['48.4%', '20.6%']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "control": "gemcitabine",
                        "phase": "3",
                        "cancer type": "pancreatic cancer"
                    },
                    "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                    "outcomes": "[6.4, 6, 24, 19, 2005]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "cell encapsulation + ifosfamide",
                        "Control": "5-fluorouracil",
                        "Phase": "2",
                        "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                        "FDA Approval": "n/a",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['10', '5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "control": "gemcitabine",
                        "phase": "3",
                        "cancer type": "pancreatic cancer"
                    },
                    "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                    "outcomes": "[6.4, 6, 24, 19, 2005]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "cell encapsulation + ifosfamide",
                        "Control": "5-fluorouracil",
                        "Phase": "2",
                        "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                        "FDA Approval": "n/a",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                    "outcomes": "['36%', '18%']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "control": "gemcitabine",
                        "phase": "3",
                        "cancer type": "pancreatic cancer",
                        "side effects": "less favorable than gemcitabine"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2005",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['6.4', '6']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "control": "gemcitabine",
                        "phase": "3",
                        "cancer type": "pancreatic cancer",
                        "side effects": "less favorable than gemcitabine"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2005",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                    "outcomes": "['24%', '19%']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                        "control": "gemcitabine",
                        "phase": "3",
                        "cancer type": "pancreatic cancer"
                    },
                    "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                    "outcomes": "[8.5, 6.7, 35, 22, 2013]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2005",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['6.4', '6']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                        "control": "gemcitabine",
                        "phase": "3",
                        "cancer type": "pancreatic cancer"
                    },
                    "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                    "outcomes": "[8.5, 6.7, 35, 22, 2013]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2013",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['8.5', '6.7']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                        "control": "gemcitabine",
                        "phase": "3",
                        "cancer type": "pancreatic cancer",
                        "side effects": "less favorable than gemcitabine"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2005",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['6.4', '6']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                        "control": "gemcitabine",
                        "phase": "3",
                        "cancer type": "pancreatic cancer",
                        "side effects": "less favorable than gemcitabine"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2013",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                    "outcomes": "['35%', '22%']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "FOLFIRINOX",
                        "control": "gemcitabine",
                        "phase": "2/3",
                        "cancer type": "pancreatic cancer"
                    },
                    "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval]",
                    "outcomes": "[11.1, 6.8, 48.4, 20.6, n/a]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2005",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['6.4', '6']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "FOLFIRINOX",
                        "control": "gemcitabine",
                        "phase": "2/3",
                        "cancer type": "pancreatic cancer"
                    },
                    "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval]",
                    "outcomes": "[11.1, 6.8, 48.4, 20.6, n/a]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "FOLFIRINOX",
                        "Control": "gemcitabine",
                        "Phase": "2/3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "n/a",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['11.1', '6.8']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "FOLFIRINOX",
                        "control": "gemcitabine",
                        "phase": "2/3",
                        "cancer type": "pancreatic cancer",
                        "side effects": "less favorable than gemcitabine"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2005",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['6.4', '6']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "FOLFIRINOX",
                        "control": "gemcitabine",
                        "phase": "2/3",
                        "cancer type": "pancreatic cancer",
                        "side effects": "less favorable than gemcitabine"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "FOLFIRINOX",
                        "Control": "gemcitabine",
                        "Phase": "2/3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "n/a",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                    "outcomes": "['48.4%', '20.6%']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "FOLFIRINOX",
                        "components": "oxaliplatin, irinotecan, fluorouracil, leucovorin"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2005",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['6.4', '6']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "FOLFIRINOX",
                        "components": "oxaliplatin, irinotecan, fluorouracil, leucovorin"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "cell encapsulation + ifosfamide",
                        "Control": "5-fluorouracil",
                        "Phase": "2",
                        "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                        "FDA Approval": "n/a",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['10', '5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "FOLFIRINOX",
                        "components": "oxaliplatin, irinotecan, fluorouracil, leucovorin"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "cell encapsulation + ifosfamide",
                        "Control": "5-fluorouracil",
                        "Phase": "2",
                        "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                        "FDA Approval": "n/a",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                    "outcomes": "['36%', '18%']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "cell encapsulation + ifosfamide",
                        "control": "5-fluorouracil",
                        "phase": "2",
                        "cancer type": "pancreatic cancer"
                    },
                    "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval]",
                    "outcomes": "[10, 5, 36, 18, n/a]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2005",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['6.4', '6']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "cell encapsulation + ifosfamide",
                        "control": "5-fluorouracil",
                        "phase": "2",
                        "cancer type": "pancreatic cancer"
                    },
                    "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval]",
                    "outcomes": "[10, 5, 36, 18, n/a]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "cell encapsulation + ifosfamide",
                        "Control": "5-fluorouracil",
                        "Phase": "2",
                        "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                        "FDA Approval": "n/a",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['10', '5']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "cell encapsulation + ifosfamide",
                        "control": "5-fluorouracil",
                        "phase": "2",
                        "cancer type": "pancreatic cancer",
                        "side effects": "more favorable than 5-fluorouracil or gemcitabine"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2005",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['6.4', '6']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "cell encapsulation + ifosfamide",
                        "control": "5-fluorouracil",
                        "phase": "2",
                        "cancer type": "pancreatic cancer",
                        "side effects": "more favorable than 5-fluorouracil or gemcitabine"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "cell encapsulation + ifosfamide",
                        "Control": "5-fluorouracil",
                        "Phase": "2",
                        "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                        "FDA Approval": "n/a",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                    "outcomes": "['36%', '18%']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "cell encapsulation + ifosfamide",
                        "dose": "2 g/m2",
                        "toxicity": "Grade 3 or Grade 4 NCI toxicities",
                        "patients affected": "five",
                        "median survival": "9.5 months"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                        "Control": "gemcitabine",
                        "Phase": "3",
                        "Side Effects": "less favorable than gemcitabine",
                        "FDA Approval": "2005",
                        "Cancer Type": "pancreatic cancer"
                    },
                    "measures": "['Median Survival Therapy', 'Median Survival Control']",
                    "outcomes": "['6.4', '6']"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 12,
        "total_ground_truth_claims": 10,
        "number_of_matches": 9
    },
    "PMC5675623_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "multivariate Cox proportional hazards regression",
                        "outcome": "overall survival",
                        "treatment phase": "first phase I",
                        "variable": "ECOG performance status",
                        "contrast": "> 0 vs. 0"
                    },
                    "measures": "[hazard ratio (95% CI), P value]",
                    "outcomes": "[1.47 (0.90, 2.41), 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "ECOG performance status",
                        "Contrast": "> 0 vs. 0",
                        "Analysis Type": "multivariate Cox proportional hazards regression",
                        "Outcome Measure": "overall survival",
                        "Treatment Phase": "first phase I"
                    },
                    "measures": "[Hazard ratio, 95% CI, p-value]",
                    "outcomes": "[1.47, 0.90-2.41, 0.12]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "multivariate Cox proportional hazards regression",
                        "outcome": "overall survival",
                        "treatment phase": "first phase I",
                        "variable": "liver metastases",
                        "contrast": "Yes vs. No"
                    },
                    "measures": "[hazard ratio (95% CI), P value]",
                    "outcomes": "[1.72 (1.01, 2.91), 0.045]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Liver metastases",
                        "Contrast": "Yes vs. No",
                        "Analysis Type": "multivariate Cox proportional hazards regression",
                        "Outcome Measure": "overall survival",
                        "Treatment Phase": "first phase I"
                    },
                    "measures": "[Hazard ratio, 95% CI, p-value]",
                    "outcomes": "[1.72, 1.01-2.91, 0.045]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "multivariate Cox proportional hazards regression",
                        "outcome": "overall survival",
                        "treatment phase": "first phase I",
                        "variable": "No. of metastatic sites",
                        "contrast": ">2 vs. <= 2"
                    },
                    "measures": "[hazard ratio (95% CI), P value]",
                    "outcomes": "[1.33 (0.9, 2.25), 0.28]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "No. of metastatic sites",
                        "Contrast": ">2 vs. <= 2",
                        "Analysis Type": "multivariate Cox proportional hazards regression",
                        "Outcome Measure": "overall survival",
                        "Treatment Phase": "first phase I"
                    },
                    "measures": "[Hazard ratio, 95% CI, p-value]",
                    "outcomes": "[1.33, 0.9-2.25, 0-28]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "multivariate Cox proportional hazards regression",
                        "outcome": "overall survival",
                        "treatment phase": "first phase I",
                        "variable": "prior radiation therapy",
                        "contrast": "Yes vs. No"
                    },
                    "measures": "[hazard ratio (95% CI), P value]",
                    "outcomes": "[1.58 (0.95, 2.61), 0.077]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Prior radiation therapy",
                        "Contrast": "Yes vs. No",
                        "Analysis Type": "multivariate Cox proportional hazards regression",
                        "Outcome Measure": "overall survival",
                        "Treatment Phase": "first phase I"
                    },
                    "measures": "[Hazard ratio, 95% CI, p-value]",
                    "outcomes": "[1.58, 0.95-2.61, 0.077]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "multivariate Cox proportional hazards regression",
                        "outcome": "overall survival",
                        "treatment phase": "first phase I",
                        "variable": "prior FOLFIRINOX",
                        "contrast": "Yes vs. No"
                    },
                    "measures": "[hazard ratio (95% CI), P value]",
                    "outcomes": "[1.73 (1.01, 2.98), 0.046]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Prior FOLFIRINOX",
                        "Contrast": "Yes vs. No",
                        "Analysis Type": "multivariate Cox proportional hazards regression",
                        "Outcome Measure": "overall survival",
                        "Treatment Phase": "first phase I"
                    },
                    "measures": "[Hazard ratio, 95% CI, p-value]",
                    "outcomes": "[1.73, 1.01-2.98, 0.046]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "multivariate Cox proportional hazards regression",
                        "outcome": "overall survival",
                        "treatment phase": "first phase I",
                        "variable": "prior gemcitabine plus nab-paclitaxel treatment",
                        "contrast": "Yes vs. No"
                    },
                    "measures": "[hazard ratio (95% CI), P value]",
                    "outcomes": "[1.08 (0.58, 2.01), 0.80]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Prior gemcitabine plus nab-paclitaxel treatment",
                        "Contrast": "Yes vs. No",
                        "Confidence Interval Lower": "0.58",
                        "Confidence Interval Upper": "2.01",
                        "Analysis Type": "multivariate Cox proportional hazards regression",
                        "Outcome Measure": "overall survival",
                        "Treatment Phase": "first phase I"
                    },
                    "measures": "[Hazard ratio, 95% CI, p-value]",
                    "outcomes": "[1.08, 0.58-2.01, 0.80]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 6,
        "total_ground_truth_claims": 6,
        "number_of_matches": 6
    },
    "PMC4742219_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Multivariable analysis for time from recurrence to death",
                        "variable": "Age",
                        "metric": "P value",
                        "outcome": "0.874"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Age",
                        "Analysis": "Multivariable",
                        "Time to event": "Time from recurrence to death"
                    },
                    "measures": "[HR, 95% CI, P value]",
                    "outcomes": "[1.00, 0.98-1.02, 0.874]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Multivariable analysis for time from recurrence to death",
                        "variable": "Gender",
                        "comparison": "female vs. male",
                        "metric": "P value",
                        "outcome": "0.544"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Gender (female vs. male)",
                        "Analysis": "Multivariable",
                        "Time to event": "Time from recurrence to death"
                    },
                    "measures": "[HR, 95% CI, P value]",
                    "outcomes": "[0.89, 0.60-1.31, 0.544]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Multivariable analysis for time from recurrence to death",
                        "variable": "Tumor size",
                        "metric": "P value",
                        "outcome": "0.127"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Tumor size",
                        "Analysis": "Multivariable",
                        "Time to event": "Time from recurrence to death"
                    },
                    "measures": "[HR, 95% CI, P value]",
                    "outcomes": "[1.13, 0.97-1.33, 0.127]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Multivariable analysis for time from recurrence to death",
                        "variable": "Tumor grade",
                        "comparison": "Grade II vs. I",
                        "metric": "P value",
                        "outcome": "0.991"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Tumor grade (Grade II vs. I)",
                        "Analysis": "Multivariable",
                        "Time to event": "Time from recurrence to death"
                    },
                    "measures": "[HR, 95% CI, P value]",
                    "outcomes": "[1.00, 0.69-1.45, 0.991]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Multivariable analysis for time from recurrence to death",
                        "variable": "Tumor grade",
                        "comparison": "Grade III vs. I",
                        "metric": "P value",
                        "outcome": "0.906"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Tumor grade (Grade III vs. I)",
                        "Analysis": "Multivariable",
                        "Time to event": "Time from recurrence to death"
                    },
                    "measures": "[HR, 95% CI, P value]",
                    "outcomes": "[0.93, 0.27-3.17, 0.906]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Multivariable analysis for time from recurrence to death",
                        "variable": "Lymph Nodes",
                        "comparison": "yes vs. no",
                        "metric": "P value",
                        "outcome": "0.229"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Lymph Nodes (yes vs. no)",
                        "Analysis": "Multivariable",
                        "Time to event": "Time from recurrence to death"
                    },
                    "measures": "[HR, 95% CI, P value]",
                    "outcomes": "[1.39, 0.81-2.38, 0.229]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Multivariable analysis for time from recurrence to death",
                        "variable": "Margin",
                        "comparison": "positive vs. negative",
                        "metric": "P value",
                        "outcome": "0.025"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Margin (positive vs. negative)",
                        "Analysis": "Multivariable",
                        "Time to event": "Time from recurrence to death"
                    },
                    "measures": "[HR, 95% CI, P value]",
                    "outcomes": "[1.54, 1.06-2.25, 0.025]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Multivariable analysis for time from recurrence to death",
                        "variable": "Vascular invasion",
                        "comparison": "yes vs. no",
                        "metric": "P value",
                        "outcome": "0.967"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Vascular invasion (yes vs. no)",
                        "Analysis": "Multivariable",
                        "Time to event": "Time from recurrence to death"
                    },
                    "measures": "[HR, 95% CI, P value]",
                    "outcomes": "[0.99, 0.69-.42, 0.967]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Multivariable analysis for time from recurrence to death",
                        "variable": "Perineural invasion",
                        "comparison": "yes vs. no",
                        "metric": "P value",
                        "outcome": "0.097"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Perineural invasion (yes vs. no)",
                        "Analysis": "Multivariable",
                        "Time to event": "Time from recurrence to death"
                    },
                    "measures": "[HR, 95% CI, P value]",
                    "outcomes": "[2.19, 0.87-5.49, 0.097]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Multivariable analysis for time from recurrence to death",
                        "variable": "Time from surgery to first recurrence",
                        "metric": "P value",
                        "outcome": "0.883"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Time from surgery to first recurrence",
                        "Analysis": "Multivariable",
                        "Time to event": "Time from recurrence to death"
                    },
                    "measures": "[HR, 95% CI, P value]",
                    "outcomes": "[1.00, 0.98-1.02, 0.883]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Multivariable analysis for time from recurrence to death",
                        "variable": "Recurrence pattern",
                        "comparison": "Lung + Other vs. Lung",
                        "metric": "P value",
                        "outcome": "0.516"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Recurrence pattern (Lung + Other vs. Lung)",
                        "Analysis": "Multivariable",
                        "Time to event": "Time from recurrence to death"
                    },
                    "measures": "[HR, 95% CI, P value]",
                    "outcomes": "[1.25, 0.63-2.48, 0.516]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Multivariable analysis for time from recurrence to death",
                        "variable": "Recurrence pattern",
                        "comparison": "Liver + Other vs. Lung",
                        "metric": "P value",
                        "outcome": "0.022"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Recurrence pattern (Liver + Other vs. Lung)",
                        "Analysis": "Multivariable",
                        "Time to event": "Time from recurrence to death"
                    },
                    "measures": "[HR, 95% CI, P value]",
                    "outcomes": "[1.91, 1.10-3.31, 0.022]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Multivariable analysis for time from recurrence to death",
                        "variable": "Recurrence pattern",
                        "comparison": "Peritoneal vs. Lung",
                        "metric": "P value",
                        "outcome": "< .001"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Recurrence pattern (Peritoneal vs. Lung)",
                        "Analysis": "Multivariable",
                        "Time to event": "Time from recurrence to death"
                    },
                    "measures": "[HR, 95% CI, P value]",
                    "outcomes": "[6.32, 3.12-12.79, <0.001]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Multivariable analysis for time from recurrence to death",
                        "variable": "Recurrence pattern",
                        "comparison": "Local vs. Lung",
                        "metric": "P value",
                        "outcome": "0.025"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Variable": "Recurrence pattern (Local vs. Lung)",
                        "Analysis": "Multivariable",
                        "Time to event": "Time from recurrence to death"
                    },
                    "measures": "[HR, 95% CI, P value]",
                    "outcomes": "[2.09, 1.10-4.00, 0.025]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 14,
        "total_ground_truth_claims": 14,
        "number_of_matches": 14
    },
    "PMC4941379_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "sample size": "4555",
                        "cases": "5",
                        "crude incidence rate": "10.42",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR2, 95% CI]",
                    "outcomes": "[Ref, Ref]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "Sample size": "4555",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['10.42']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "sample size": "4555",
                        "cases": "5",
                        "crude incidence rate": "10.42",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR2, 95% CI]",
                    "outcomes": "[Ref, Ref]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "Sample size": "4555",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[Ref, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "sample size": "4555",
                        "cases": "5",
                        "crude incidence rate": "10.42",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR2, 95% CI]",
                    "outcomes": "[Ref, Ref]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "Sample size": "4555",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years",
                        "HR2 description": "comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR2, 95% CI]",
                    "outcomes": "[Ref, NA]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "1984",
                        "cases": "2",
                        "crude incidence rate": "9.54",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[Ref, 0.79, 0.15, 4.08]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "Sample size": "4555",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['10.42']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "1984",
                        "cases": "2",
                        "crude incidence rate": "9.54",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[Ref, 0.79, 0.15, 4.08]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "Sample size": "4555",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[Ref, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "1984",
                        "cases": "2",
                        "crude incidence rate": "9.54",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[Ref, 0.79, 0.15, 4.08]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "1984",
                        "Cases": "2",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['9.54']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "1984",
                        "cases": "2",
                        "crude incidence rate": "9.54",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[Ref, 0.79, 0.15, 4.08]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "1984",
                        "Cases": "2",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[NA, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "1984",
                        "cases": "2",
                        "crude incidence rate": "9.54",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[Ref, 0.79, 0.15, 4.08]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "1984",
                        "Cases": "2",
                        "Unit": ", Per 100,000 person-years",
                        "HR2 description": "comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR2, 95% CI]",
                    "outcomes": "[0.79, (0.15-4.08)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "2295",
                        "cases": "14",
                        "crude incidence rate": "58.13",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[Ref, 5.05, 1.81, 14.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "Sample size": "4555",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['10.42']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "2295",
                        "cases": "14",
                        "crude incidence rate": "58.13",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[Ref, 5.05, 1.81, 14.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "Sample size": "4555",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[Ref, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "2295",
                        "cases": "14",
                        "crude incidence rate": "58.13",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[Ref, 5.05, 1.81, 14.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "1984",
                        "Cases": "2",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['9.54']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "2295",
                        "cases": "14",
                        "crude incidence rate": "58.13",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[Ref, 5.05, 1.81, 14.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "1984",
                        "Cases": "2",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[NA, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "2295",
                        "cases": "14",
                        "crude incidence rate": "58.13",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[Ref, 5.05, 1.81, 14.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "Sample size": "2295",
                        "Cases": "14",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['58.13']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "2295",
                        "cases": "14",
                        "crude incidence rate": "58.13",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[Ref, 5.05, 1.81, 14.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "Sample size": "2295",
                        "Cases": "14",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[NA, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "2295",
                        "cases": "14",
                        "crude incidence rate": "58.13",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[Ref, 5.05, 1.81, 14.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "Sample size": "2295",
                        "Cases": "14",
                        "Unit": ", Per 100,000 person-years",
                        "HR2 description": "comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR2, 95% CI]",
                    "outcomes": "[5.05, (1.81-14.09)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "sample size": "205",
                        "cases": "0",
                        "crude incidence rate": "0",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, Not estimable, 1.38, 8.64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "Sample size": "4555",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['10.42']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "sample size": "205",
                        "cases": "0",
                        "crude incidence rate": "0",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, Not estimable, 1.38, 8.64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "Sample size": "4555",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[Ref, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "sample size": "205",
                        "cases": "0",
                        "crude incidence rate": "0",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, Not estimable, 1.38, 8.64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "1984",
                        "Cases": "2",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['9.54']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "sample size": "205",
                        "cases": "0",
                        "crude incidence rate": "0",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, Not estimable, 1.38, 8.64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "1984",
                        "Cases": "2",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[NA, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "sample size": "205",
                        "cases": "0",
                        "crude incidence rate": "0",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, Not estimable, 1.38, 8.64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "Sample size": "2295",
                        "Cases": "14",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['58.13']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "sample size": "205",
                        "cases": "0",
                        "crude incidence rate": "0",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, Not estimable, 1.38, 8.64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "Sample size": "2295",
                        "Cases": "14",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[NA, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "sample size": "205",
                        "cases": "0",
                        "crude incidence rate": "0",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, Not estimable, 1.38, 8.64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG-/CagA-",
                        "Sample size": "205",
                        "Cases": "0",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "sample size": "205",
                        "cases": "0",
                        "crude incidence rate": "0",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, Not estimable, 1.38, 8.64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG-/CagA-",
                        "Sample size": "205",
                        "Cases": "0",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[3.45, (1.38-8.64)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "143",
                        "cases": "1",
                        "crude incidence rate": "64.61",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 5.50, 0.63, 47.57]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "Sample size": "4555",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['10.42']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "143",
                        "cases": "1",
                        "crude incidence rate": "64.61",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 5.50, 0.63, 47.57]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "Sample size": "4555",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[Ref, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "143",
                        "cases": "1",
                        "crude incidence rate": "64.61",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 5.50, 0.63, 47.57]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "1984",
                        "Cases": "2",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['9.54']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "143",
                        "cases": "1",
                        "crude incidence rate": "64.61",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 5.50, 0.63, 47.57]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "1984",
                        "Cases": "2",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[NA, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "143",
                        "cases": "1",
                        "crude incidence rate": "64.61",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 5.50, 0.63, 47.57]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "Sample size": "2295",
                        "Cases": "14",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['58.13']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "143",
                        "cases": "1",
                        "crude incidence rate": "64.61",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 5.50, 0.63, 47.57]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "Sample size": "2295",
                        "Cases": "14",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[NA, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "143",
                        "cases": "1",
                        "crude incidence rate": "64.61",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 5.50, 0.63, 47.57]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG-/CagA-",
                        "Sample size": "205",
                        "Cases": "0",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "143",
                        "cases": "1",
                        "crude incidence rate": "64.61",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 5.50, 0.63, 47.57]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG-/CagA-",
                        "Sample size": "205",
                        "Cases": "0",
                        "Unit": ", Per 100,000 person-years",
                        "HR2 description": "comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR2, 95% CI]",
                    "outcomes": "[NA, Not estimable]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "143",
                        "cases": "1",
                        "crude incidence rate": "64.61",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 5.50, 0.63, 47.57]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "143",
                        "Cases": "1",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['64.61']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "143",
                        "cases": "1",
                        "crude incidence rate": "64.61",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 5.50, 0.63, 47.57]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "143",
                        "Cases": "1",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[NA, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA\u2212",
                        "sample size": "143",
                        "cases": "1",
                        "crude incidence rate": "64.61",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 5.50, 0.63, 47.57]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "143",
                        "Cases": "1",
                        "Unit": ", Per 100,000 person-years",
                        "HR2 description": "comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR2, 95% CI]",
                    "outcomes": "[5.50, (0.63-47.57)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "315",
                        "cases": "5",
                        "crude incidence rate": "151.20",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 12.51, 3.57, 43.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "Sample size": "4555",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['10.42']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "315",
                        "cases": "5",
                        "crude incidence rate": "151.20",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 12.51, 3.57, 43.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG\u2212/CagA\u2212",
                        "Sample size": "4555",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[Ref, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "315",
                        "cases": "5",
                        "crude incidence rate": "151.20",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 12.51, 3.57, 43.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "1984",
                        "Cases": "2",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['9.54']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "315",
                        "cases": "5",
                        "crude incidence rate": "151.20",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 12.51, 3.57, 43.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "1984",
                        "Cases": "2",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[NA, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "315",
                        "cases": "5",
                        "crude incidence rate": "151.20",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 12.51, 3.57, 43.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "Sample size": "2295",
                        "Cases": "14",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['58.13']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "315",
                        "cases": "5",
                        "crude incidence rate": "151.20",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 12.51, 3.57, 43.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "None",
                        "H. pylori infection": "IgG+/CagA+",
                        "Sample size": "2295",
                        "Cases": "14",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[NA, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "315",
                        "cases": "5",
                        "crude incidence rate": "151.20",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 12.51, 3.57, 43.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG-/CagA-",
                        "Sample size": "205",
                        "Cases": "0",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "315",
                        "cases": "5",
                        "crude incidence rate": "151.20",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 12.51, 3.57, 43.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG-/CagA-",
                        "Sample size": "205",
                        "Cases": "0",
                        "Unit": ", Per 100,000 person-years",
                        "HR2 description": "comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR2, 95% CI]",
                    "outcomes": "[NA, Not estimable]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "315",
                        "cases": "5",
                        "crude incidence rate": "151.20",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 12.51, 3.57, 43.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "143",
                        "Cases": "1",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['64.61']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "315",
                        "cases": "5",
                        "crude incidence rate": "151.20",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 12.51, 3.57, 43.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA-",
                        "Sample size": "143",
                        "Cases": "1",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[NA, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "315",
                        "cases": "5",
                        "crude incidence rate": "151.20",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 12.51, 3.57, 43.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "Sample size": "315",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years"
                    },
                    "measures": "['Crude incidence rate']",
                    "outcomes": "['151.20']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "315",
                        "cases": "5",
                        "crude incidence rate": "151.20",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 12.51, 3.57, 43.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "Sample size": "315",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years",
                        "HR1 description": "comparing participants with and without chronic atrophic gastritis",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR1, 95% CI]",
                    "outcomes": "[NA, NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "sample size": "315",
                        "cases": "5",
                        "crude incidence rate": "151.20",
                        "crude incidence rate unit": "per 100,000 person-years",
                        "HR1 adjustment": "age, sex, education level, smoking status and alcohol consumption",
                        "HR2 adjustment": "age, sex, education level, smoking status and alcohol consumption"
                    },
                    "measures": "[HR1, HR2, 95% CI lower, 95% CI upper]",
                    "outcomes": "[3.45, 12.51, 3.57, 43.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Chronic atrophic gastritis": "Present",
                        "H. pylori infection": "IgG+/CagA+",
                        "Sample size": "315",
                        "Cases": "5",
                        "Unit": ", Per 100,000 person-years",
                        "HR2 description": "comparing different groups with participants without chronic atrophic gastritis and without H. pylori infection",
                        "Adjustment factors": ", age, sex, education level, smoking status, alcohol consumption"
                    },
                    "measures": "[HR2, 95% CI]",
                    "outcomes": "[12.51, (3.57-43.22)]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 6,
        "total_ground_truth_claims": 18,
        "number_of_matches": 6
    },
    "PMC3987090_5": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "An X et al.",
                        "year": "2010",
                        "n": "89",
                        "number of patients with NLR >5": "16",
                        "percentage of patients with NLR >5": "17.9%",
                        "overall survival NLR >5": "2.4 months",
                        "overall survival NLR \u22645": "7.7 months",
                        "hazard ratio": "4.49",
                        "p-value": "0.013",
                        "reference": "16",
                        "condition": "APC patients receiving chemotherapy"
                    },
                    "measures": "[overall survival difference, hazard ratio, p-value]",
                    "outcomes": "[5.3 months, 4.49, 0.013]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Study": "An X et al.",
                        "Year": "2010",
                        "number of patients": "89",
                        "Number of patientis with NLR > 5 (%)": "16 (17.9)",
                        "Overall survival (NLR >5 vs \u22645) (months)": "2.4 versus 7.7",
                        "NLR \u22645": "1"
                    },
                    "measures": "[Hazard Ratio, P-Value]",
                    "outcomes": "[4.49, 0.013]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Wang DS et al.",
                        "year": "2012",
                        "n": "86",
                        "number of patients with NLR >5": "12",
                        "percentage of patients with NLR >5": "13.9%",
                        "overall survival NLR >5": "5.8 months",
                        "overall survival NLR \u22645": "10.2 months",
                        "reference": "17",
                        "condition": "APC patients receiving chemotherapy"
                    },
                    "measures": "[overall survival difference]",
                    "outcomes": "[4.4 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Study": "Wang DS et al.",
                        "Year": "2012",
                        "number of patients": "86",
                        "Number of patientis with NLR > 5 (%)": "12 (13.9)",
                        "Overall survival (NLR >5 vs \u22645) (months)": "5.8 versus 10.2",
                        "NLR \u22645": "1"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Stotz M et al",
                        "year": "2013",
                        "n": "261",
                        "number of patients with NLR >5": "79",
                        "percentage of patients with NLR >5": "30.3%",
                        "hazard ratio": "2.53",
                        "p-value": "<0.01",
                        "reference": "17",
                        "condition": "APC patients receiving chemotherapy and no chemotherapy",
                        "note": "This study (n = 261) pooled the data from patients who received chemotherapy (n = 179) and no chemotherapy (n = 82)"
                    },
                    "measures": "[hazard ratio, p-value]",
                    "outcomes": "[2.53, <0.01]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Study": "Stotz M et al.",
                        "Year": "2013",
                        "number of patients": "261",
                        "number of patients who received chemotherapy": "179",
                        "number of patients who did not received chemotherapy": "82",
                        "Number of patientis with NLR > 5 (%)": "79 (30.3)",
                        "Overall survival (NLR >5 vs \u22645) (months)": "NA",
                        "NLR \u22645": "1"
                    },
                    "measures": "[Hazard Ratio, P-Value]",
                    "outcomes": "[2.53, <0.01]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Our study",
                        "year": "2013",
                        "n": "253",
                        "number of patients with NLR >5": "40",
                        "percentage of patients with NLR >5": "15.8%",
                        "overall survival NLR >5": "6.0 months",
                        "overall survival NLR \u22645": "12.8 months",
                        "hazard ratio": "1.95",
                        "p-value": "<0.01",
                        "condition": "APC patients receiving chemotherapy"
                    },
                    "measures": "[overall survival difference, hazard ratio, p-value]",
                    "outcomes": "[6.8 months, 1.95, <0.01]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Study": "Our study",
                        "Year": "2013",
                        "number of patients": "253",
                        "Number of patientis with NLR > 5 (%)": "40 (15.8)",
                        "Overall survival (NLR >5 vs \u22645) (months)": "6.0 versus 12.8",
                        "NLR \u22645": "1"
                    },
                    "measures": "[Hazard Ratio, P-Value]",
                    "outcomes": "[1.95, <0.01]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 4,
        "total_ground_truth_claims": 4,
        "number_of_matches": 4
    },
    "PMC4728116_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "family history of pancreatic cancer": "no",
                        "cases": "312",
                        "cases percentage": "96.6",
                        "controls": "320",
                        "controls percentage": "99.1",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "family history of pancreatic cancer": "yes",
                        "cases": "11",
                        "cases percentage": "3.4",
                        "controls": "3",
                        "controls percentage": "0.9",
                        "crude OR": "3.67",
                        "crude CI": "1.02\u201313.14",
                        "adjusted OR1": "4.04",
                        "adjusted CI1": "1.08\u201315.07",
                        "adjusted OR2": "1.23",
                        "adjusted CI2": "1.11\u20133.70",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[3.67, 4.04, 1.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted  OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "family history of pancreatic cancer": "yes",
                        "cases": "11",
                        "cases percentage": "3.4",
                        "controls": "3",
                        "controls percentage": "0.9",
                        "crude OR": "3.67",
                        "crude CI": "1.02\u201313.14",
                        "adjusted OR1": "4.04",
                        "adjusted CI1": "1.08\u201315.07",
                        "adjusted OR2": "1.23",
                        "adjusted CI2": "1.11\u20133.70",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[3.67, 4.04, 1.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "family history of pancreatic cancer": "yes",
                        "cases": "11",
                        "cases percentage": "3.4",
                        "controls": "3",
                        "controls percentage": "0.9",
                        "crude OR": "3.67",
                        "crude CI": "1.02\u201313.14",
                        "adjusted OR1": "4.04",
                        "adjusted CI1": "1.08\u201315.07",
                        "adjusted OR2": "1.23",
                        "adjusted CI2": "1.11\u20133.70",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[3.67, 4.04, 1.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[3.67, (1.02\u201313.14)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "BMI": "<24.0",
                        "cases": "197",
                        "cases percentage": "61.0",
                        "controls": "230",
                        "controls percentage": "71.2",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted  OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "BMI": "<24.0",
                        "cases": "197",
                        "cases percentage": "61.0",
                        "controls": "230",
                        "controls percentage": "71.2",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "BMI": "<24.0",
                        "cases": "197",
                        "cases percentage": "61.0",
                        "controls": "230",
                        "controls percentage": "71.2",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[4.04, (1.08\u201315.07)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "BMI": "<24.0",
                        "cases": "197",
                        "cases percentage": "61.0",
                        "controls": "230",
                        "controls percentage": "71.2",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.23, (1.11\u20133.70)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "BMI": "<24.0",
                        "cases": "197",
                        "cases percentage": "61.0",
                        "controls": "230",
                        "controls percentage": "71.2",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "<24.0",
                        "cases_n": "197",
                        "cases_percentage": "61.0",
                        "controls_n": "230",
                        "controls_percentage": "71.2"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "BMI": "\u226524.0",
                        "cases": "126",
                        "cases percentage": "39.0",
                        "controls": "93",
                        "controls percentage": "28.8",
                        "crude OR": "1.67",
                        "crude CI": "1.18\u20132.38",
                        "adjusted OR1": "1.78",
                        "adjusted CI1": "1.23\u20132.58",
                        "adjusted OR2": "1.77",
                        "adjusted CI2": "1.22\u20132.57",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.67, 1.78, 1.77]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted  OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "BMI": "\u226524.0",
                        "cases": "126",
                        "cases percentage": "39.0",
                        "controls": "93",
                        "controls percentage": "28.8",
                        "crude OR": "1.67",
                        "crude CI": "1.18\u20132.38",
                        "adjusted OR1": "1.78",
                        "adjusted CI1": "1.23\u20132.58",
                        "adjusted OR2": "1.77",
                        "adjusted CI2": "1.22\u20132.57",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.67, 1.78, 1.77]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "BMI": "\u226524.0",
                        "cases": "126",
                        "cases percentage": "39.0",
                        "controls": "93",
                        "controls percentage": "28.8",
                        "crude OR": "1.67",
                        "crude CI": "1.18\u20132.38",
                        "adjusted OR1": "1.78",
                        "adjusted CI1": "1.23\u20132.58",
                        "adjusted OR2": "1.77",
                        "adjusted CI2": "1.22\u20132.57",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.67, 1.78, 1.77]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[4.04, (1.08\u201315.07)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "BMI": "\u226524.0",
                        "cases": "126",
                        "cases percentage": "39.0",
                        "controls": "93",
                        "controls percentage": "28.8",
                        "crude OR": "1.67",
                        "crude CI": "1.18\u20132.38",
                        "adjusted OR1": "1.78",
                        "adjusted CI1": "1.23\u20132.58",
                        "adjusted OR2": "1.77",
                        "adjusted CI2": "1.22\u20132.57",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.67, 1.78, 1.77]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.23, (1.11\u20133.70)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "BMI": "\u226524.0",
                        "cases": "126",
                        "cases percentage": "39.0",
                        "controls": "93",
                        "controls percentage": "28.8",
                        "crude OR": "1.67",
                        "crude CI": "1.18\u20132.38",
                        "adjusted OR1": "1.78",
                        "adjusted CI1": "1.23\u20132.58",
                        "adjusted OR2": "1.77",
                        "adjusted CI2": "1.22\u20132.57",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.67, 1.78, 1.77]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "<24.0",
                        "cases_n": "197",
                        "cases_percentage": "61.0",
                        "controls_n": "230",
                        "controls_percentage": "71.2",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "BMI": "\u226524.0",
                        "cases": "126",
                        "cases percentage": "39.0",
                        "controls": "93",
                        "controls percentage": "28.8",
                        "crude OR": "1.67",
                        "crude CI": "1.18\u20132.38",
                        "adjusted OR1": "1.78",
                        "adjusted CI1": "1.23\u20132.58",
                        "adjusted OR2": "1.77",
                        "adjusted CI2": "1.22\u20132.57",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.67, 1.78, 1.77]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "<24.0",
                        "cases_n": "197",
                        "cases_percentage": "61.0",
                        "controls_n": "230",
                        "controls_percentage": "71.2",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "BMI": "\u226524.0",
                        "cases": "126",
                        "cases percentage": "39.0",
                        "controls": "93",
                        "controls percentage": "28.8",
                        "crude OR": "1.67",
                        "crude CI": "1.18\u20132.38",
                        "adjusted OR1": "1.78",
                        "adjusted CI1": "1.23\u20132.58",
                        "adjusted OR2": "1.77",
                        "adjusted CI2": "1.22\u20132.57",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.67, 1.78, 1.77]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "\u226524.0",
                        "cases_n": "126",
                        "cases_percentage": "39.0",
                        "controls_n": "93",
                        "controls_percentage": "28.8"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[1.67, (1.18\u20132.38)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "BMI": "\u226524.0",
                        "cases": "126",
                        "cases percentage": "39.0",
                        "controls": "93",
                        "controls percentage": "28.8",
                        "crude OR": "1.67",
                        "crude CI": "1.18\u20132.38",
                        "adjusted OR1": "1.78",
                        "adjusted CI1": "1.23\u20132.58",
                        "adjusted OR2": "1.77",
                        "adjusted CI2": "1.22\u20132.57",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.67, 1.78, 1.77]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "\u226524.0",
                        "cases_n": "126",
                        "cases_percentage": "39.0",
                        "controls_n": "93",
                        "controls_percentage": "28.8",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.78, (1.23\u20132.58)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "no",
                        "cases": "174",
                        "cases percentage": "78.0",
                        "controls": "255",
                        "controls percentage": "90.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted  OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "no",
                        "cases": "174",
                        "cases percentage": "78.0",
                        "controls": "255",
                        "controls percentage": "90.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "no",
                        "cases": "174",
                        "cases percentage": "78.0",
                        "controls": "255",
                        "controls percentage": "90.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[4.04, (1.08\u201315.07)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "no",
                        "cases": "174",
                        "cases percentage": "78.0",
                        "controls": "255",
                        "controls percentage": "90.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.23, (1.11\u20133.70)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "no",
                        "cases": "174",
                        "cases percentage": "78.0",
                        "controls": "255",
                        "controls percentage": "90.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "<24.0",
                        "cases_n": "197",
                        "cases_percentage": "61.0",
                        "controls_n": "230",
                        "controls_percentage": "71.2",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "no",
                        "cases": "174",
                        "cases percentage": "78.0",
                        "controls": "255",
                        "controls percentage": "90.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "<24.0",
                        "cases_n": "197",
                        "cases_percentage": "61.0",
                        "controls_n": "230",
                        "controls_percentage": "71.2",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "no",
                        "cases": "174",
                        "cases percentage": "78.0",
                        "controls": "255",
                        "controls percentage": "90.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "\u226524.0",
                        "cases_n": "126",
                        "cases_percentage": "39.0",
                        "controls_n": "93",
                        "controls_percentage": "28.8"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[1.67, (1.18\u20132.38)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "no",
                        "cases": "174",
                        "cases percentage": "78.0",
                        "controls": "255",
                        "controls percentage": "90.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "\u226524.0",
                        "cases_n": "126",
                        "cases_percentage": "39.0",
                        "controls_n": "93",
                        "controls_percentage": "28.8",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.77, (1.22\u20132.57)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "no",
                        "cases": "174",
                        "cases percentage": "78.0",
                        "controls": "255",
                        "controls percentage": "90.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "No",
                        "cases_n": "174",
                        "cases_percentage": "78.0",
                        "controls_n": "255",
                        "controls_percentage": "90.7"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "yes",
                        "cases": "49",
                        "cases percentage": "22.0",
                        "controls": "26",
                        "controls percentage": "9.3",
                        "crude OR": "2.69",
                        "crude CI": "1.51\u20134.77",
                        "adjusted OR1": "2.60",
                        "adjusted CI1": "1.41\u20134.79",
                        "adjusted OR2": "2.96",
                        "adjusted CI2": "1.48\u20135.92",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.69, 2.60, 2.96]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted  OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "yes",
                        "cases": "49",
                        "cases percentage": "22.0",
                        "controls": "26",
                        "controls percentage": "9.3",
                        "crude OR": "2.69",
                        "crude CI": "1.51\u20134.77",
                        "adjusted OR1": "2.60",
                        "adjusted CI1": "1.41\u20134.79",
                        "adjusted OR2": "2.96",
                        "adjusted CI2": "1.48\u20135.92",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.69, 2.60, 2.96]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "yes",
                        "cases": "49",
                        "cases percentage": "22.0",
                        "controls": "26",
                        "controls percentage": "9.3",
                        "crude OR": "2.69",
                        "crude CI": "1.51\u20134.77",
                        "adjusted OR1": "2.60",
                        "adjusted CI1": "1.41\u20134.79",
                        "adjusted OR2": "2.96",
                        "adjusted CI2": "1.48\u20135.92",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.69, 2.60, 2.96]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[4.04, (1.08\u201315.07)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "yes",
                        "cases": "49",
                        "cases percentage": "22.0",
                        "controls": "26",
                        "controls percentage": "9.3",
                        "crude OR": "2.69",
                        "crude CI": "1.51\u20134.77",
                        "adjusted OR1": "2.60",
                        "adjusted CI1": "1.41\u20134.79",
                        "adjusted OR2": "2.96",
                        "adjusted CI2": "1.48\u20135.92",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.69, 2.60, 2.96]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.23, (1.11\u20133.70)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "yes",
                        "cases": "49",
                        "cases percentage": "22.0",
                        "controls": "26",
                        "controls percentage": "9.3",
                        "crude OR": "2.69",
                        "crude CI": "1.51\u20134.77",
                        "adjusted OR1": "2.60",
                        "adjusted CI1": "1.41\u20134.79",
                        "adjusted OR2": "2.96",
                        "adjusted CI2": "1.48\u20135.92",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.69, 2.60, 2.96]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "<24.0",
                        "cases_n": "197",
                        "cases_percentage": "61.0",
                        "controls_n": "230",
                        "controls_percentage": "71.2",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "yes",
                        "cases": "49",
                        "cases percentage": "22.0",
                        "controls": "26",
                        "controls percentage": "9.3",
                        "crude OR": "2.69",
                        "crude CI": "1.51\u20134.77",
                        "adjusted OR1": "2.60",
                        "adjusted CI1": "1.41\u20134.79",
                        "adjusted OR2": "2.96",
                        "adjusted CI2": "1.48\u20135.92",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.69, 2.60, 2.96]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "<24.0",
                        "cases_n": "197",
                        "cases_percentage": "61.0",
                        "controls_n": "230",
                        "controls_percentage": "71.2",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "yes",
                        "cases": "49",
                        "cases percentage": "22.0",
                        "controls": "26",
                        "controls percentage": "9.3",
                        "crude OR": "2.69",
                        "crude CI": "1.51\u20134.77",
                        "adjusted OR1": "2.60",
                        "adjusted CI1": "1.41\u20134.79",
                        "adjusted OR2": "2.96",
                        "adjusted CI2": "1.48\u20135.92",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.69, 2.60, 2.96]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "\u226524.0",
                        "cases_n": "126",
                        "cases_percentage": "39.0",
                        "controls_n": "93",
                        "controls_percentage": "28.8"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[1.67, (1.18\u20132.38)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "yes",
                        "cases": "49",
                        "cases percentage": "22.0",
                        "controls": "26",
                        "controls percentage": "9.3",
                        "crude OR": "2.69",
                        "crude CI": "1.51\u20134.77",
                        "adjusted OR1": "2.60",
                        "adjusted CI1": "1.41\u20134.79",
                        "adjusted OR2": "2.96",
                        "adjusted CI2": "1.48\u20135.92",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.69, 2.60, 2.96]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "\u226524.0",
                        "cases_n": "126",
                        "cases_percentage": "39.0",
                        "controls_n": "93",
                        "controls_percentage": "28.8",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.77, (1.22\u20132.57)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "yes",
                        "cases": "49",
                        "cases percentage": "22.0",
                        "controls": "26",
                        "controls percentage": "9.3",
                        "crude OR": "2.69",
                        "crude CI": "1.51\u20134.77",
                        "adjusted OR1": "2.60",
                        "adjusted CI1": "1.41\u20134.79",
                        "adjusted OR2": "2.96",
                        "adjusted CI2": "1.48\u20135.92",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.69, 2.60, 2.96]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "No",
                        "cases_n": "174",
                        "cases_percentage": "78.0",
                        "controls_n": "255",
                        "controls_percentage": "90.7",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "yes",
                        "cases": "49",
                        "cases percentage": "22.0",
                        "controls": "26",
                        "controls percentage": "9.3",
                        "crude OR": "2.69",
                        "crude CI": "1.51\u20134.77",
                        "adjusted OR1": "2.60",
                        "adjusted CI1": "1.41\u20134.79",
                        "adjusted OR2": "2.96",
                        "adjusted CI2": "1.48\u20135.92",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.69, 2.60, 2.96]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "No",
                        "cases_n": "174",
                        "cases_percentage": "78.0",
                        "controls_n": "255",
                        "controls_percentage": "90.7",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "yes",
                        "cases": "49",
                        "cases percentage": "22.0",
                        "controls": "26",
                        "controls percentage": "9.3",
                        "crude OR": "2.69",
                        "crude CI": "1.51\u20134.77",
                        "adjusted OR1": "2.60",
                        "adjusted CI1": "1.41\u20134.79",
                        "adjusted OR2": "2.96",
                        "adjusted CI2": "1.48\u20135.92",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.69, 2.60, 2.96]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "Yes",
                        "cases_n": "49",
                        "cases_percentage": "22.0",
                        "controls_n": "26",
                        "controls_percentage": "9.3"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[2.69, (1.51\u20134.77)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "diabetes",
                        "diabetes": "yes",
                        "cases": "49",
                        "cases percentage": "22.0",
                        "controls": "26",
                        "controls percentage": "9.3",
                        "crude OR": "2.69",
                        "crude CI": "1.51\u20134.77",
                        "adjusted OR1": "2.60",
                        "adjusted CI1": "1.41\u20134.79",
                        "adjusted OR2": "2.96",
                        "adjusted CI2": "1.48\u20135.92",
                        "statistical significance": "yes"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.69, 2.60, 2.96]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "Yes",
                        "cases_n": "49",
                        "cases_percentage": "22.0",
                        "controls_n": "26",
                        "controls_percentage": "9.3",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[2.60, (1.41\u20134.79)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "no",
                        "cases": "272",
                        "cases percentage": "94.1",
                        "controls": "195",
                        "controls percentage": "96.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted  OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "no",
                        "cases": "272",
                        "cases percentage": "94.1",
                        "controls": "195",
                        "controls percentage": "96.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "no",
                        "cases": "272",
                        "cases percentage": "94.1",
                        "controls": "195",
                        "controls percentage": "96.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[4.04, (1.08\u201315.07)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "no",
                        "cases": "272",
                        "cases percentage": "94.1",
                        "controls": "195",
                        "controls percentage": "96.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.23, (1.11\u20133.70)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "no",
                        "cases": "272",
                        "cases percentage": "94.1",
                        "controls": "195",
                        "controls percentage": "96.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "<24.0",
                        "cases_n": "197",
                        "cases_percentage": "61.0",
                        "controls_n": "230",
                        "controls_percentage": "71.2",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "no",
                        "cases": "272",
                        "cases percentage": "94.1",
                        "controls": "195",
                        "controls percentage": "96.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "<24.0",
                        "cases_n": "197",
                        "cases_percentage": "61.0",
                        "controls_n": "230",
                        "controls_percentage": "71.2",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "no",
                        "cases": "272",
                        "cases percentage": "94.1",
                        "controls": "195",
                        "controls percentage": "96.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "\u226524.0",
                        "cases_n": "126",
                        "cases_percentage": "39.0",
                        "controls_n": "93",
                        "controls_percentage": "28.8"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[1.67, (1.18\u20132.38)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "no",
                        "cases": "272",
                        "cases percentage": "94.1",
                        "controls": "195",
                        "controls percentage": "96.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "\u226524.0",
                        "cases_n": "126",
                        "cases_percentage": "39.0",
                        "controls_n": "93",
                        "controls_percentage": "28.8",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.77, (1.22\u20132.57)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "no",
                        "cases": "272",
                        "cases percentage": "94.1",
                        "controls": "195",
                        "controls percentage": "96.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "No",
                        "cases_n": "174",
                        "cases_percentage": "78.0",
                        "controls_n": "255",
                        "controls_percentage": "90.7",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "no",
                        "cases": "272",
                        "cases percentage": "94.1",
                        "controls": "195",
                        "controls percentage": "96.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "No",
                        "cases_n": "174",
                        "cases_percentage": "78.0",
                        "controls_n": "255",
                        "controls_percentage": "90.7",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "no",
                        "cases": "272",
                        "cases percentage": "94.1",
                        "controls": "195",
                        "controls percentage": "96.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "Yes",
                        "cases_n": "49",
                        "cases_percentage": "22.0",
                        "controls_n": "26",
                        "controls_percentage": "9.3"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[2.69, (1.51\u20134.77)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "no",
                        "cases": "272",
                        "cases percentage": "94.1",
                        "controls": "195",
                        "controls percentage": "96.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "Yes",
                        "cases_n": "49",
                        "cases_percentage": "22.0",
                        "controls_n": "26",
                        "controls_percentage": "9.3",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[2.96, (1.48\u20135.92)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "no",
                        "cases": "272",
                        "cases percentage": "94.1",
                        "controls": "195",
                        "controls percentage": "96.7",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Cholecystitis",
                        "group": "No",
                        "cases_n": "272",
                        "cases_percentage": "94.1",
                        "controls_n": "195",
                        "controls_percentage": "96.7"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "yes",
                        "cases": "17",
                        "cases percentage": "5.9",
                        "controls": "10",
                        "controls percentage": "3.3",
                        "crude OR": "1.89",
                        "crude CI": "0.84\u20134.24",
                        "adjusted OR1": "1.91",
                        "adjusted CI1": "0.83\u20134.38",
                        "adjusted OR2": "1.35",
                        "adjusted CI2": "0.50\u20133.68",
                        "statistical significance": "no"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.89, 1.91, 1.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted  OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "yes",
                        "cases": "17",
                        "cases percentage": "5.9",
                        "controls": "10",
                        "controls percentage": "3.3",
                        "crude OR": "1.89",
                        "crude CI": "0.84\u20134.24",
                        "adjusted OR1": "1.91",
                        "adjusted CI1": "0.83\u20134.38",
                        "adjusted OR2": "1.35",
                        "adjusted CI2": "0.50\u20133.68",
                        "statistical significance": "no"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.89, 1.91, 1.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "yes",
                        "cases": "17",
                        "cases percentage": "5.9",
                        "controls": "10",
                        "controls percentage": "3.3",
                        "crude OR": "1.89",
                        "crude CI": "0.84\u20134.24",
                        "adjusted OR1": "1.91",
                        "adjusted CI1": "0.83\u20134.38",
                        "adjusted OR2": "1.35",
                        "adjusted CI2": "0.50\u20133.68",
                        "statistical significance": "no"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.89, 1.91, 1.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[4.04, (1.08\u201315.07)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "yes",
                        "cases": "17",
                        "cases percentage": "5.9",
                        "controls": "10",
                        "controls percentage": "3.3",
                        "crude OR": "1.89",
                        "crude CI": "0.84\u20134.24",
                        "adjusted OR1": "1.91",
                        "adjusted CI1": "0.83\u20134.38",
                        "adjusted OR2": "1.35",
                        "adjusted CI2": "0.50\u20133.68",
                        "statistical significance": "no"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.89, 1.91, 1.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.23, (1.11\u20133.70)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "yes",
                        "cases": "17",
                        "cases percentage": "5.9",
                        "controls": "10",
                        "controls percentage": "3.3",
                        "crude OR": "1.89",
                        "crude CI": "0.84\u20134.24",
                        "adjusted OR1": "1.91",
                        "adjusted CI1": "0.83\u20134.38",
                        "adjusted OR2": "1.35",
                        "adjusted CI2": "0.50\u20133.68",
                        "statistical significance": "no"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.89, 1.91, 1.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "<24.0",
                        "cases_n": "197",
                        "cases_percentage": "61.0",
                        "controls_n": "230",
                        "controls_percentage": "71.2",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "yes",
                        "cases": "17",
                        "cases percentage": "5.9",
                        "controls": "10",
                        "controls percentage": "3.3",
                        "crude OR": "1.89",
                        "crude CI": "0.84\u20134.24",
                        "adjusted OR1": "1.91",
                        "adjusted CI1": "0.83\u20134.38",
                        "adjusted OR2": "1.35",
                        "adjusted CI2": "0.50\u20133.68",
                        "statistical significance": "no"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.89, 1.91, 1.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "<24.0",
                        "cases_n": "197",
                        "cases_percentage": "61.0",
                        "controls_n": "230",
                        "controls_percentage": "71.2",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "yes",
                        "cases": "17",
                        "cases percentage": "5.9",
                        "controls": "10",
                        "controls percentage": "3.3",
                        "crude OR": "1.89",
                        "crude CI": "0.84\u20134.24",
                        "adjusted OR1": "1.91",
                        "adjusted CI1": "0.83\u20134.38",
                        "adjusted OR2": "1.35",
                        "adjusted CI2": "0.50\u20133.68",
                        "statistical significance": "no"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.89, 1.91, 1.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "\u226524.0",
                        "cases_n": "126",
                        "cases_percentage": "39.0",
                        "controls_n": "93",
                        "controls_percentage": "28.8"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[1.67, (1.18\u20132.38)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "yes",
                        "cases": "17",
                        "cases percentage": "5.9",
                        "controls": "10",
                        "controls percentage": "3.3",
                        "crude OR": "1.89",
                        "crude CI": "0.84\u20134.24",
                        "adjusted OR1": "1.91",
                        "adjusted CI1": "0.83\u20134.38",
                        "adjusted OR2": "1.35",
                        "adjusted CI2": "0.50\u20133.68",
                        "statistical significance": "no"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.89, 1.91, 1.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "\u226524.0",
                        "cases_n": "126",
                        "cases_percentage": "39.0",
                        "controls_n": "93",
                        "controls_percentage": "28.8",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.77, (1.22\u20132.57)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "yes",
                        "cases": "17",
                        "cases percentage": "5.9",
                        "controls": "10",
                        "controls percentage": "3.3",
                        "crude OR": "1.89",
                        "crude CI": "0.84\u20134.24",
                        "adjusted OR1": "1.91",
                        "adjusted CI1": "0.83\u20134.38",
                        "adjusted OR2": "1.35",
                        "adjusted CI2": "0.50\u20133.68",
                        "statistical significance": "no"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.89, 1.91, 1.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "No",
                        "cases_n": "174",
                        "cases_percentage": "78.0",
                        "controls_n": "255",
                        "controls_percentage": "90.7",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "yes",
                        "cases": "17",
                        "cases percentage": "5.9",
                        "controls": "10",
                        "controls percentage": "3.3",
                        "crude OR": "1.89",
                        "crude CI": "0.84\u20134.24",
                        "adjusted OR1": "1.91",
                        "adjusted CI1": "0.83\u20134.38",
                        "adjusted OR2": "1.35",
                        "adjusted CI2": "0.50\u20133.68",
                        "statistical significance": "no"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.89, 1.91, 1.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "No",
                        "cases_n": "174",
                        "cases_percentage": "78.0",
                        "controls_n": "255",
                        "controls_percentage": "90.7",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "yes",
                        "cases": "17",
                        "cases percentage": "5.9",
                        "controls": "10",
                        "controls percentage": "3.3",
                        "crude OR": "1.89",
                        "crude CI": "0.84\u20134.24",
                        "adjusted OR1": "1.91",
                        "adjusted CI1": "0.83\u20134.38",
                        "adjusted OR2": "1.35",
                        "adjusted CI2": "0.50\u20133.68",
                        "statistical significance": "no"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.89, 1.91, 1.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "Yes",
                        "cases_n": "49",
                        "cases_percentage": "22.0",
                        "controls_n": "26",
                        "controls_percentage": "9.3"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[2.69, (1.51\u20134.77)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "yes",
                        "cases": "17",
                        "cases percentage": "5.9",
                        "controls": "10",
                        "controls percentage": "3.3",
                        "crude OR": "1.89",
                        "crude CI": "0.84\u20134.24",
                        "adjusted OR1": "1.91",
                        "adjusted CI1": "0.83\u20134.38",
                        "adjusted OR2": "1.35",
                        "adjusted CI2": "0.50\u20133.68",
                        "statistical significance": "no"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.89, 1.91, 1.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "Yes",
                        "cases_n": "49",
                        "cases_percentage": "22.0",
                        "controls_n": "26",
                        "controls_percentage": "9.3",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[2.96, (1.48\u20135.92)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "yes",
                        "cases": "17",
                        "cases percentage": "5.9",
                        "controls": "10",
                        "controls percentage": "3.3",
                        "crude OR": "1.89",
                        "crude CI": "0.84\u20134.24",
                        "adjusted OR1": "1.91",
                        "adjusted CI1": "0.83\u20134.38",
                        "adjusted OR2": "1.35",
                        "adjusted CI2": "0.50\u20133.68",
                        "statistical significance": "no"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.89, 1.91, 1.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Cholecystitis",
                        "group": "No",
                        "cases_n": "272",
                        "cases_percentage": "94.1",
                        "controls_n": "195",
                        "controls_percentage": "96.7",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "yes",
                        "cases": "17",
                        "cases percentage": "5.9",
                        "controls": "10",
                        "controls percentage": "3.3",
                        "crude OR": "1.89",
                        "crude CI": "0.84\u20134.24",
                        "adjusted OR1": "1.91",
                        "adjusted CI1": "0.83\u20134.38",
                        "adjusted OR2": "1.35",
                        "adjusted CI2": "0.50\u20133.68",
                        "statistical significance": "no"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.89, 1.91, 1.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Cholecystitis",
                        "group": "No",
                        "cases_n": "272",
                        "cases_percentage": "94.1",
                        "controls_n": "195",
                        "controls_percentage": "96.7",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "cholecystitis",
                        "cholecystitis": "yes",
                        "cases": "17",
                        "cases percentage": "5.9",
                        "controls": "10",
                        "controls percentage": "3.3",
                        "crude OR": "1.89",
                        "crude CI": "0.84\u20134.24",
                        "adjusted OR1": "1.91",
                        "adjusted CI1": "0.83\u20134.38",
                        "adjusted OR2": "1.35",
                        "adjusted CI2": "0.50\u20133.68",
                        "statistical significance": "no"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.89, 1.91, 1.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Cholecystitis",
                        "group": "Yes",
                        "cases_n": "17",
                        "cases_percentage": "5.9",
                        "controls_n": "10",
                        "controls_percentage": "3.3"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[1.89, (0.84\u20134.24)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted  OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[4.04, (1.08\u201315.07)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.23, (1.11\u20133.70)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "<24.0",
                        "cases_n": "197",
                        "cases_percentage": "61.0",
                        "controls_n": "230",
                        "controls_percentage": "71.2",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "<24.0",
                        "cases_n": "197",
                        "cases_percentage": "61.0",
                        "controls_n": "230",
                        "controls_percentage": "71.2",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "\u226524.0",
                        "cases_n": "126",
                        "cases_percentage": "39.0",
                        "controls_n": "93",
                        "controls_percentage": "28.8"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[1.67, (1.18\u20132.38)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "\u226524.0",
                        "cases_n": "126",
                        "cases_percentage": "39.0",
                        "controls_n": "93",
                        "controls_percentage": "28.8",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.77, (1.22\u20132.57)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "No",
                        "cases_n": "174",
                        "cases_percentage": "78.0",
                        "controls_n": "255",
                        "controls_percentage": "90.7",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "No",
                        "cases_n": "174",
                        "cases_percentage": "78.0",
                        "controls_n": "255",
                        "controls_percentage": "90.7",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "Yes",
                        "cases_n": "49",
                        "cases_percentage": "22.0",
                        "controls_n": "26",
                        "controls_percentage": "9.3"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[2.69, (1.51\u20134.77)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "Yes",
                        "cases_n": "49",
                        "cases_percentage": "22.0",
                        "controls_n": "26",
                        "controls_percentage": "9.3",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[2.96, (1.48\u20135.92)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Cholecystitis",
                        "group": "No",
                        "cases_n": "272",
                        "cases_percentage": "94.1",
                        "controls_n": "195",
                        "controls_percentage": "96.7",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Cholecystitis",
                        "group": "No",
                        "cases_n": "272",
                        "cases_percentage": "94.1",
                        "controls_n": "195",
                        "controls_percentage": "96.7",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Cholecystitis",
                        "group": "Yes",
                        "cases_n": "17",
                        "cases_percentage": "5.9",
                        "controls_n": "10",
                        "controls_percentage": "3.3",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.91, (0.83\u20134.38)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Cholecystitis",
                        "group": "Yes",
                        "cases_n": "17",
                        "cases_percentage": "5.9",
                        "controls_n": "10",
                        "controls_percentage": "3.3",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.35, (0.50\u20133.68)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "no",
                        "cases": "274",
                        "cases percentage": "95.1",
                        "controls": "300",
                        "controls percentage": "98.4",
                        "crude OR": "1.00",
                        "crude CI": "reference",
                        "adjusted OR1": "1.00",
                        "adjusted CI1": "reference",
                        "adjusted OR2": "1.00",
                        "adjusted CI2": "reference"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[1.00, 1.00, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Gallstone",
                        "group": "No",
                        "cases_n": "274",
                        "cases_percentage": "95.1",
                        "controls_n": "300",
                        "controls_percentage": "98.4"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted  OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "no",
                        "cases_n": "312",
                        "cases_percentage": "96.6",
                        "controls_n": "320",
                        "controls_percentage": "99.1",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[4.04, (1.08\u201315.07)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "family history of pancreatic cancer",
                        "group": "yes",
                        "cases_n": "11",
                        "cases_percentage": "3.4",
                        "controls_n": "3",
                        "controls_percentage": "0.9",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.23, (1.11\u20133.70)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "<24.0",
                        "cases_n": "197",
                        "cases_percentage": "61.0",
                        "controls_n": "230",
                        "controls_percentage": "71.2",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "<24.0",
                        "cases_n": "197",
                        "cases_percentage": "61.0",
                        "controls_n": "230",
                        "controls_percentage": "71.2",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "\u226524.0",
                        "cases_n": "126",
                        "cases_percentage": "39.0",
                        "controls_n": "93",
                        "controls_percentage": "28.8"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[1.67, (1.18\u20132.38)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "BMI",
                        "group": "\u226524.0",
                        "cases_n": "126",
                        "cases_percentage": "39.0",
                        "controls_n": "93",
                        "controls_percentage": "28.8",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.77, (1.22\u20132.57)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "No",
                        "cases_n": "174",
                        "cases_percentage": "78.0",
                        "controls_n": "255",
                        "controls_percentage": "90.7",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "No",
                        "cases_n": "174",
                        "cases_percentage": "78.0",
                        "controls_n": "255",
                        "controls_percentage": "90.7",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "Yes",
                        "cases_n": "49",
                        "cases_percentage": "22.0",
                        "controls_n": "26",
                        "controls_percentage": "9.3"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[2.69, (1.51\u20134.77)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Diabetes",
                        "group": "Yes",
                        "cases_n": "49",
                        "cases_percentage": "22.0",
                        "controls_n": "26",
                        "controls_percentage": "9.3",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[2.96, (1.48\u20135.92)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Cholecystitis",
                        "group": "No",
                        "cases_n": "272",
                        "cases_percentage": "94.1",
                        "controls_n": "195",
                        "controls_percentage": "96.7",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Cholecystitis",
                        "group": "No",
                        "cases_n": "272",
                        "cases_percentage": "94.1",
                        "controls_n": "195",
                        "controls_percentage": "96.7",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Cholecystitis",
                        "group": "Yes",
                        "cases_n": "17",
                        "cases_percentage": "5.9",
                        "controls_n": "10",
                        "controls_percentage": "3.3",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.91, (0.83\u20134.38)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Cholecystitis",
                        "group": "Yes",
                        "cases_n": "17",
                        "cases_percentage": "5.9",
                        "controls_n": "10",
                        "controls_percentage": "3.3",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.35, (0.50\u20133.68)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Gallstone",
                        "group": "No",
                        "cases_n": "274",
                        "cases_percentage": "95.1",
                        "controls_n": "300",
                        "controls_percentage": "98.4",
                        "adjustment": "Adjusted for age, sex, race, and residential areas."
                    },
                    "measures": "[Adjusted OR1, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Gallstone",
                        "group": "No",
                        "cases_n": "274",
                        "cases_percentage": "95.1",
                        "controls_n": "300",
                        "controls_percentage": "98.4",
                        "adjustment": "Adjusted for age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables."
                    },
                    "measures": "[Adjusted OR2, 95% CI]",
                    "outcomes": "[1.00 (reference), NA]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "characteristic": "gallstone",
                        "gallstone": "yes",
                        "cases": "14",
                        "cases percentage": "4.9",
                        "controls": "5",
                        "controls percentage": "1.6",
                        "crude OR": "2.80",
                        "crude CI": "1.01\u20137.77",
                        "adjusted OR1": "2.58",
                        "adjusted CI1": "0.89\u20137.44",
                        "adjusted OR2": "2.68",
                        "adjusted CI2": "0.65\u201311.07",
                        "statistical significance": "partial"
                    },
                    "measures": "[crude OR, adjusted OR1, adjusted OR2]",
                    "outcomes": "[2.80, 2.58, 2.68]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "characteristic": "Gallstone",
                        "group": "Yes",
                        "cases_n": "14",
                        "cases_percentage": "4.9",
                        "controls_n": "5",
                        "controls_percentage": "1.6"
                    },
                    "measures": "[Crude OR, 95% CI]",
                    "outcomes": "[2.80, (1.01\u20137.77)]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 10,
        "total_ground_truth_claims": 30,
        "number_of_matches": 10
    },
    "PMC4741511_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "Sorafenib group",
                        "LDH level": "\u2264 UNR",
                        "patients number": "31",
                        "patients percentage": "44%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[7.6 months, 12.7 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "31",
                        "patients percentage": "44%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[7.6, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "Sorafenib group",
                        "LDH level": "\u2264 UNR",
                        "patients number": "31",
                        "patients percentage": "44%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[7.6 months, 12.7 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "31",
                        "patients percentage": "44%",
                        "unit": "months"
                    },
                    "measures": "[OS, p]",
                    "outcomes": "[12.7, 0.0012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "Sorafenib group",
                        "LDH level": "\u2264 UNR",
                        "patients number": "31",
                        "patients percentage": "44%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[7.6 months, 12.7 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH > UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "6",
                        "patients percentage": "8%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[2.8, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "Sorafenib group",
                        "LDH level": "\u2264 UNR",
                        "patients number": "31",
                        "patients percentage": "44%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[7.6 months, 12.7 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH > UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "6",
                        "patients percentage": "8%",
                        "PFS (months)": "2.8",
                        "OS (months)": "5.9",
                        "PFS p-value": "0.05",
                        "OS p-value": "0.0012",
                        "unit": "months"
                    },
                    "measures": "[OS, p]",
                    "outcomes": "[5.9, 0.0012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "Sorafenib group",
                        "LDH level": "\u2264 UNR",
                        "patients number": "31",
                        "patients percentage": "44%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[7.6 months, 12.7 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "27",
                        "patients percentage": "38%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[3.3, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "Sorafenib group",
                        "LDH level": "\u2264 UNR",
                        "patients number": "31",
                        "patients percentage": "44%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[7.6 months, 12.7 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "27",
                        "patients percentage": "38%",
                        "unit": "months"
                    },
                    "measures": "[OS, p]",
                    "outcomes": "[8.6, 0.0012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "Sorafenib group",
                        "LDH level": "\u2264 UNR",
                        "patients number": "31",
                        "patients percentage": "44%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[7.6 months, 12.7 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH > UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "7",
                        "patients percentage": "10%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[2.2, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "Sorafenib group",
                        "LDH level": "\u2264 UNR",
                        "patients number": "31",
                        "patients percentage": "44%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[7.6 months, 12.7 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH > UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "7",
                        "patients percentage": "10%",
                        "unit": "months"
                    },
                    "measures": "[OS, p]",
                    "outcomes": "[5.2, 0.0012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "Sorafenib group",
                        "LDH level": "> UNR",
                        "patients number": "6",
                        "patients percentage": "8%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[2.8 months, 5.9 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "31",
                        "patients percentage": "44%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[7.6, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "Sorafenib group",
                        "LDH level": "> UNR",
                        "patients number": "6",
                        "patients percentage": "8%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[2.8 months, 5.9 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "31",
                        "patients percentage": "44%",
                        "unit": "months"
                    },
                    "measures": "[OS, p]",
                    "outcomes": "[12.7, 0.0012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "Sorafenib group",
                        "LDH level": "> UNR",
                        "patients number": "6",
                        "patients percentage": "8%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[2.8 months, 5.9 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH > UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "6",
                        "patients percentage": "8%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[2.8, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "Sorafenib group",
                        "LDH level": "> UNR",
                        "patients number": "6",
                        "patients percentage": "8%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[2.8 months, 5.9 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH > UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "6",
                        "patients percentage": "8%",
                        "PFS (months)": "2.8",
                        "OS (months)": "5.9",
                        "PFS p-value": "0.05",
                        "OS p-value": "0.0012",
                        "unit": "months"
                    },
                    "measures": "[OS, p]",
                    "outcomes": "[5.9, 0.0012]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "No Sorafenib group",
                        "LDH level": "\u2264 UNR",
                        "patients number": "27",
                        "patients percentage": "38%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[3.3 months, 8.6 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "31",
                        "patients percentage": "44%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[7.6, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "No Sorafenib group",
                        "LDH level": "\u2264 UNR",
                        "patients number": "27",
                        "patients percentage": "38%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[3.3 months, 8.6 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "31",
                        "patients percentage": "44%",
                        "unit": "months"
                    },
                    "measures": "[OS, p]",
                    "outcomes": "[12.7, 0.0012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "No Sorafenib group",
                        "LDH level": "\u2264 UNR",
                        "patients number": "27",
                        "patients percentage": "38%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[3.3 months, 8.6 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH > UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "6",
                        "patients percentage": "8%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[2.8, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "No Sorafenib group",
                        "LDH level": "\u2264 UNR",
                        "patients number": "27",
                        "patients percentage": "38%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[3.3 months, 8.6 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "27",
                        "patients percentage": "38%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[3.3, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "No Sorafenib group",
                        "LDH level": "\u2264 UNR",
                        "patients number": "27",
                        "patients percentage": "38%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[3.3 months, 8.6 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "27",
                        "patients percentage": "38%",
                        "unit": "months"
                    },
                    "measures": "[OS, p]",
                    "outcomes": "[8.6, 0.0012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "No Sorafenib group",
                        "LDH level": "\u2264 UNR",
                        "patients number": "27",
                        "patients percentage": "38%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[3.3 months, 8.6 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH > UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "7",
                        "patients percentage": "10%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[2.2, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "No Sorafenib group",
                        "LDH level": "\u2264 UNR",
                        "patients number": "27",
                        "patients percentage": "38%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[3.3 months, 8.6 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH > UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "7",
                        "patients percentage": "10%",
                        "unit": "months"
                    },
                    "measures": "[OS, p]",
                    "outcomes": "[5.2, 0.0012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "No Sorafenib group",
                        "LDH level": "> UNR",
                        "patients number": "7",
                        "patients percentage": "10%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[2.2 months, 5.2 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "31",
                        "patients percentage": "44%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[7.6, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "No Sorafenib group",
                        "LDH level": "> UNR",
                        "patients number": "7",
                        "patients percentage": "10%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[2.2 months, 5.2 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "31",
                        "patients percentage": "44%",
                        "unit": "months"
                    },
                    "measures": "[OS, p]",
                    "outcomes": "[12.7, 0.0012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "No Sorafenib group",
                        "LDH level": "> UNR",
                        "patients number": "7",
                        "patients percentage": "10%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[2.2 months, 5.2 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH > UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "6",
                        "patients percentage": "8%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[2.8, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "No Sorafenib group",
                        "LDH level": "> UNR",
                        "patients number": "7",
                        "patients percentage": "10%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[2.2 months, 5.2 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "27",
                        "patients percentage": "38%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[3.3, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "No Sorafenib group",
                        "LDH level": "> UNR",
                        "patients number": "7",
                        "patients percentage": "10%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[2.2 months, 5.2 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "27",
                        "patients percentage": "38%",
                        "unit": "months"
                    },
                    "measures": "[OS, p]",
                    "outcomes": "[8.6, 0.0012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "No Sorafenib group",
                        "LDH level": "> UNR",
                        "patients number": "7",
                        "patients percentage": "10%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[2.2 months, 5.2 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH > UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "7",
                        "patients percentage": "10%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[2.2, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment",
                        "treatment group": "No Sorafenib group",
                        "LDH level": "> UNR",
                        "patients number": "7",
                        "patients percentage": "10%"
                    },
                    "measures": "[PFS, OS]",
                    "outcomes": "[2.2 months, 5.2 months]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH > UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "7",
                        "patients percentage": "10%",
                        "unit": "months"
                    },
                    "measures": "[OS, p]",
                    "outcomes": "[5.2, 0.0012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment"
                    },
                    "measures": "[p-value for PFS, p-value for OS]",
                    "outcomes": "[0.05, 0.0012]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "31",
                        "patients percentage": "44%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[7.6, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment"
                    },
                    "measures": "[p-value for PFS, p-value for OS]",
                    "outcomes": "[0.05, 0.0012]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "31",
                        "patients percentage": "44%",
                        "unit": "months"
                    },
                    "measures": "[OS, p]",
                    "outcomes": "[12.7, 0.0012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment"
                    },
                    "measures": "[p-value for PFS, p-value for OS]",
                    "outcomes": "[0.05, 0.0012]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "Sorafenib group",
                        "LDH level": "LDH > UNR",
                        "treatment": "chemotherapy plus sorafenib",
                        "patients number": "6",
                        "patients percentage": "8%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[2.8, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment"
                    },
                    "measures": "[p-value for PFS, p-value for OS]",
                    "outcomes": "[0.05, 0.0012]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "27",
                        "patients percentage": "38%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[3.3, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment"
                    },
                    "measures": "[p-value for PFS, p-value for OS]",
                    "outcomes": "[0.05, 0.0012]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH \u2264 UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "27",
                        "patients percentage": "38%",
                        "unit": "months"
                    },
                    "measures": "[OS, p]",
                    "outcomes": "[8.6, 0.0012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment"
                    },
                    "measures": "[p-value for PFS, p-value for OS]",
                    "outcomes": "[0.05, 0.0012]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH > UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "7",
                        "patients percentage": "10%",
                        "unit": "months"
                    },
                    "measures": "[PFS, p]",
                    "outcomes": "[2.2, 0.05]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "population": "stratified according to LDH serum levels and treatment"
                    },
                    "measures": "[p-value for PFS, p-value for OS]",
                    "outcomes": "[0.05, 0.0012]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "study": "MAPS phase II",
                        "analysis": "PFS and OS",
                        "population subgroup": "No Sorafenib group",
                        "LDH level": "LDH > UNR",
                        "treatment": "chemotherapy alone",
                        "patients number": "7",
                        "patients percentage": "10%",
                        "unit": "months"
                    },
                    "measures": "[OS, p]",
                    "outcomes": "[5.2, 0.0012]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 5,
        "total_ground_truth_claims": 8,
        "number_of_matches": 1
    },
    "PMC5522086_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Inhibition",
                        "upstream regulator": "TP53",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[activation z-score, p-value of overlap]",
                    "outcomes": "[-2.353, 3.34\u00d710^-32]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "TP53",
                        "Regulation Type": "Inhibition",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[-2.353, 3.34E-32]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Inhibition",
                        "upstream regulator": "NUPR1",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[log ratio, activation z-score, p-value of overlap]",
                    "outcomes": "[-2.52, -3.977, 4.62\u00d710^-13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "NUPR1",
                        "Regulation Type": "Inhibition",
                        "Log Ratio": "-2.52",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[-3.977, 4.62E-13]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Inhibition",
                        "upstream regulator": "NKX2-3",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[activation z-score, p-value of overlap]",
                    "outcomes": "[-3.455, 5.88\u00d710^-12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "NKX2-3",
                        "Regulation Type": "Inhibition",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[-3.455, 5.88E-12]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Inhibition",
                        "upstream regulator": "HNF1A",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[activation z-score, p-value of overlap]",
                    "outcomes": "[-2.359, 8.82\u00d710^-12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "HNF1A",
                        "Regulation Type": "Inhibition",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[-2.359, 8.82E-12]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Inhibition",
                        "upstream regulator": "CDKN2A",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[log ratio, activation z-score, p-value of overlap]",
                    "outcomes": "[1.737, -3.219, 1.34\u00d710^-11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "CDKN2A",
                        "Regulation Type": "Inhibition",
                        "Log Ratio": "1.737",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[-3.219, 1.34E-11]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Inhibition",
                        "upstream regulator": "estrogen receptor",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[activation z-score, p-value of overlap]",
                    "outcomes": "[-2.299, 9.57\u00d710^-10]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "estrogen receptor",
                        "Regulation Type": "Inhibition",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[-2.299, 9.57E-10]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Inhibition",
                        "upstream regulator": "RB1",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[activation z-score, p-value of overlap]",
                    "outcomes": "[-4.286, 3.74\u00d710^-08]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "RB1",
                        "Regulation Type": "Inhibition",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[-4.286, 3.74E-08]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Inhibition",
                        "upstream regulator": "TCF3",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[activation z-score, p-value of overlap]",
                    "outcomes": "[-3.116, 4.32\u00d710^-08]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "TCF3",
                        "Regulation Type": "Inhibition",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[-3.116, 4.32E-08]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Inhibition",
                        "upstream regulator": "TRIM24",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[activation z-score, p-value of overlap]",
                    "outcomes": "[-3.714, 6.26\u00d710^-07]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "TRIM24",
                        "Regulation Type": "Inhibition",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[-3.714, 6.26E-07]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Inhibition",
                        "upstream regulator": "BCL6",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[activation z-score, p-value of overlap]",
                    "outcomes": "[-2.313, 1.60\u00d710^-06]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "BCL6",
                        "Regulation Type": "Inhibition",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[-2.313, 1.60E-06]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Inhibition",
                        "upstream regulator": "NR5A2",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[log ratio, activation z-score, p-value of overlap]",
                    "outcomes": "[-2.876, -2.7, 7.26\u00d710^-06]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "NR5A2",
                        "Regulation Type": "Inhibition",
                        "Log Ratio": "-2.876",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[-2.7, 7.26E-06]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Inhibition",
                        "upstream regulator": "SATB1",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[log ratio, activation z-score, p-value of overlap]",
                    "outcomes": "[-0.814, -2.003, 1.09\u00d710^-05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "SATB1",
                        "Regulation Type": "Inhibition",
                        "Log Ratio": "-0814",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[-2.003, 1.09E-05]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Inhibition",
                        "upstream regulator": "IRF4",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[log ratio, activation z-score, p-value of overlap]",
                    "outcomes": "[2.115, -2.41, 4.24\u00d710^-05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "IRF4",
                        "Regulation Type": "Inhibition",
                        "Log Ratio": "2.115",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[-2.41, 4.24E-05]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Inhibition",
                        "upstream regulator": "RBL1",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[activation z-score, p-value of overlap]",
                    "outcomes": "[-3.124, 1.72\u00d710^-04]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "RBL1",
                        "Regulation Type": "Inhibition",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[-3.124, 1.72E-04]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Inhibition",
                        "upstream regulator": "SPDEF",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[activation z-score, p-value of overlap]",
                    "outcomes": "[-2.887, 2.39\u00d710^-04]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "SPDEF",
                        "Regulation Type": "Inhibition",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[-2.887, 2.39E-04]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Activation",
                        "upstream regulator": "STAT3",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[activation z-score, p-value of overlap]",
                    "outcomes": "[2.924, 5.78\u00d710^-19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "STAT3",
                        "Regulation Type": "Activation",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[2.924, 5.78E-19]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Top 15 significant upstream transcription regulators",
                        "regulation": "Activation",
                        "upstream regulator": "CTNNB1",
                        "activation z-score definition": "statistical parameter that determines whether an upstream transcription regulator has significantly more \"activated\" predictions than \"inhibited\" predictions (z>0) or vice versa (z<0)",
                        "p-value of overlap definition": "measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcriptional regulator",
                        "p-value calculation method": "Fisher's Exact Test",
                        "p-value significance threshold": "< 0.01"
                    },
                    "measures": "[activation z-score, p-value of overlap]",
                    "outcomes": "[3.359, 1.99\u00d710^-15]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Upstream Regulator": "CTNNB1",
                        "Regulation Type": "Activation",
                        "Statistical significant overlap": "Fisher's Exact Test"
                    },
                    "measures": "[Activation z-score, P-value of overlap]",
                    "outcomes": "[3.359, 1.99E-15]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 17,
        "total_ground_truth_claims": 30,
        "number_of_matches": 17
    },
    "PMC4941331_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "tissue type": "tumor tissue",
                        "CDH1 expression location": "cytoplasmic",
                        "CDH1 expression level": "low",
                        "HDAC3 expression location": "nuclear",
                        "HDAC3 expression level": "low"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "Tumor tissue sample": "Cytoplasmic CDH1 Low",
                        "Nuclear HDAC3 expression": "Low",
                        "Tumor tissue sample count": "34",
                        "Correlation measure": "Spearman correlation coefficient"
                    },
                    "measures": "[Spearman correlation coefficient]",
                    "outcomes": "[0.440]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "tissue type": "tumor tissue",
                        "CDH1 expression location": "cytoplasmic",
                        "CDH1 expression level": "low",
                        "HDAC3 expression location": "nuclear",
                        "HDAC3 expression level": "low"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "Tumor tissue sample": "Cytoplasmic CDH1 Low",
                        "Nuclear HDAC3 expression": "High",
                        "Tumor tissue sample count": "22",
                        "Correlation measure": "Spearman correlation coefficient"
                    },
                    "measures": "[Spearman correlation coefficient, P-value]",
                    "outcomes": "[0.440, < 0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "tissue type": "tumor tissue",
                        "CDH1 expression location": "cytoplasmic",
                        "CDH1 expression level": "low",
                        "HDAC3 expression location": "nuclear",
                        "HDAC3 expression level": "low"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "Tumor tissue sample": "Cytoplasmic CDH1 High",
                        "Nuclear HDAC3 expression": "Low",
                        "Tumor tissue sample count": "4",
                        "Correlation measure": "Spearman correlation coefficient"
                    },
                    "measures": "[Spearman correlation coefficient, P-value]",
                    "outcomes": "[0.440, < 0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "tissue type": "tumor tissue",
                        "CDH1 expression location": "cytoplasmic",
                        "CDH1 expression level": "low",
                        "HDAC3 expression location": "nuclear",
                        "HDAC3 expression level": "low"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "Tumor tissue sample": "Cytoplasmic CDH1 High",
                        "Nuclear HDAC3 expression": "High",
                        "Tumor tissue sample count": "24",
                        "Correlation measure": "Spearman correlation coefficient"
                    },
                    "measures": "[Spearman correlation coefficient, P-value]",
                    "outcomes": "[0.440, < 0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "tissue type": "tumor tissue",
                        "CDH1 expression location": "cytoplasmic",
                        "CDH1 expression level": "low",
                        "HDAC3 expression location": "nuclear",
                        "HDAC3 expression level": "high"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "Tumor tissue sample": "Cytoplasmic CDH1 Low",
                        "Nuclear HDAC3 expression": "Low",
                        "Tumor tissue sample count": "34",
                        "Correlation measure": "Spearman correlation coefficient"
                    },
                    "measures": "[Spearman correlation coefficient]",
                    "outcomes": "[0.440]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "tissue type": "tumor tissue",
                        "CDH1 expression location": "cytoplasmic",
                        "CDH1 expression level": "low",
                        "HDAC3 expression location": "nuclear",
                        "HDAC3 expression level": "high"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "Tumor tissue sample": "Cytoplasmic CDH1 Low",
                        "Nuclear HDAC3 expression": "High",
                        "Tumor tissue sample count": "22",
                        "Correlation measure": "Spearman correlation coefficient"
                    },
                    "measures": "[Spearman correlation coefficient, P-value]",
                    "outcomes": "[0.440, < 0.001]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "tissue type": "tumor tissue",
                        "CDH1 expression location": "cytoplasmic",
                        "CDH1 expression level": "high",
                        "HDAC3 expression location": "nuclear",
                        "HDAC3 expression level": "low"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "Tumor tissue sample": "Cytoplasmic CDH1 Low",
                        "Nuclear HDAC3 expression": "Low",
                        "Tumor tissue sample count": "34",
                        "Correlation measure": "Spearman correlation coefficient"
                    },
                    "measures": "[Spearman correlation coefficient]",
                    "outcomes": "[0.440]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "tissue type": "tumor tissue",
                        "CDH1 expression location": "cytoplasmic",
                        "CDH1 expression level": "high",
                        "HDAC3 expression location": "nuclear",
                        "HDAC3 expression level": "low"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "Tumor tissue sample": "Cytoplasmic CDH1 High",
                        "Nuclear HDAC3 expression": "Low",
                        "Tumor tissue sample count": "4",
                        "Correlation measure": "Spearman correlation coefficient"
                    },
                    "measures": "[Spearman correlation coefficient, P-value]",
                    "outcomes": "[0.440, < 0.001]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "tissue type": "tumor tissue",
                        "CDH1 expression location": "cytoplasmic",
                        "CDH1 expression level": "high",
                        "HDAC3 expression location": "nuclear",
                        "HDAC3 expression level": "high"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[24]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "Tumor tissue sample": "Cytoplasmic CDH1 Low",
                        "Nuclear HDAC3 expression": "Low",
                        "Tumor tissue sample count": "34",
                        "Correlation measure": "Spearman correlation coefficient"
                    },
                    "measures": "[Spearman correlation coefficient]",
                    "outcomes": "[0.440]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "tissue type": "tumor tissue",
                        "CDH1 expression location": "cytoplasmic",
                        "CDH1 expression level": "high",
                        "HDAC3 expression location": "nuclear",
                        "HDAC3 expression level": "high"
                    },
                    "measures": "[sample count]",
                    "outcomes": "[24]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "Tumor tissue sample": "Cytoplasmic CDH1 High",
                        "Nuclear HDAC3 expression": "High",
                        "Tumor tissue sample count": "24",
                        "Correlation measure": "Spearman correlation coefficient"
                    },
                    "measures": "[Spearman correlation coefficient, P-value]",
                    "outcomes": "[0.440, < 0.001]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "tissue type": "tumor tissue",
                        "CDH1 expression location": "cytoplasmic",
                        "HDAC3 expression location": "nuclear",
                        "statistical test": "Spearman correlation"
                    },
                    "measures": "[correlation coefficient, P-value]",
                    "outcomes": "[0.440, < 0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "Tumor tissue sample": "Cytoplasmic CDH1 Low",
                        "Nuclear HDAC3 expression": "Low",
                        "Tumor tissue sample count": "34",
                        "Correlation measure": "Spearman correlation coefficient"
                    },
                    "measures": "[Spearman correlation coefficient]",
                    "outcomes": "[0.440]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "association between membrane CDH1 and nuclear HDAC3 expression",
                        "tissue type": "tumor tissue",
                        "CDH1 expression location": "membrane",
                        "HDAC3 expression location": "nuclear",
                        "statistical test": "Spearman correlation"
                    },
                    "measures": "[correlation coefficient, P-value]",
                    "outcomes": "[-0.348, 0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "Tumor tissue sample": "Cytoplasmic CDH1 Low",
                        "Nuclear HDAC3 expression": "Low",
                        "Tumor tissue sample count": "34",
                        "Correlation measure": "Spearman correlation coefficient"
                    },
                    "measures": "[Spearman correlation coefficient]",
                    "outcomes": "[0.440]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "association between cytoplasmic HDAC3 and CDH1 expression",
                        "tissue type": "tumor tissue",
                        "HDAC3 expression location": "cytoplasmic",
                        "CDH1 expression location": "any",
                        "statistical test": "not specified"
                    },
                    "measures": "[P-value]",
                    "outcomes": "[> 0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                        "Tumor tissue sample": "Cytoplasmic CDH1 Low",
                        "Nuclear HDAC3 expression": "Low",
                        "Tumor tissue sample count": "34",
                        "Correlation measure": "Spearman correlation coefficient"
                    },
                    "measures": "[Spearman correlation coefficient]",
                    "outcomes": "[0.440]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 7,
        "total_ground_truth_claims": 4,
        "number_of_matches": 3
    },
    "PMC6062623_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "hypothesis": "state transition",
                        "graph metric": "local efficiency",
                        "hemisphere": "right",
                        "density (k)": "0.1"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-3.76, 0.002]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Hypothesis": "State transition",
                        "Graph metric": "Local efficiency",
                        "Hemisphere": "Right",
                        "Density (k)": "0.1"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-3.76, 0.002]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "hypothesis": "state transition",
                        "graph metric": "local efficiency",
                        "hemisphere": "right",
                        "density (k)": "0.15"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-3.15, 0.008]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Hypothesis": "State transition",
                        "Graph metric": "Local efficiency",
                        "Hemisphere": "Right",
                        "Density (k)": "0.15"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-3.15, 0.008]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "hypothesis": "state transition",
                        "graph metric": "local efficiency",
                        "hemisphere": "right",
                        "density (k)": "0.2"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-3.25, 0.006]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Hypothesis": "State transition",
                        "Graph metric": "Local efficiency",
                        "Hemisphere": "Right",
                        "Density (k)": "0.2"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-3.25, 0.006]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "hypothesis": "state transition",
                        "graph metric": "local efficiency",
                        "hemisphere": "right",
                        "density (k)": "0.25"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-3.08, 0.009]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Hypothesis": "State transition",
                        "Graph metric": "Local efficiency",
                        "Hemisphere": "Right",
                        "Density (k)": "0.25"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-3.08, 0.009]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "hypothesis": "state transition",
                        "graph metric": "local efficiency",
                        "hemisphere": "left",
                        "density (k)": "0.1"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-1.04, 0.32]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Hypothesis": "State transition",
                        "Graph metric": "Local efficiency",
                        "Hemisphere": "Right",
                        "Density (k)": "0.1"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-1.04, 0.32]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "hypothesis": "state transition",
                        "graph metric": "local efficiency",
                        "hemisphere": "left",
                        "density (k)": "0.15"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-2.58, 0.022]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Hypothesis": "State transition",
                        "Graph metric": "Local efficiency",
                        "Hemisphere": "Right",
                        "Density (k)": "0.15"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-2.58, 0.022]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "hypothesis": "state transition",
                        "graph metric": "local efficiency",
                        "hemisphere": "left",
                        "density (k)": "0.2"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-3.36, 0.005]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Hypothesis": "State transition",
                        "Graph metric": "Local efficiency",
                        "Hemisphere": "Right",
                        "Density (k)": "0.2"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-3.36, 0.005]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "hypothesis": "state transition",
                        "graph metric": "local efficiency",
                        "hemisphere": "left",
                        "density (k)": "0.25"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-3.04, 0.01]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Hypothesis": "State transition",
                        "Graph metric": "Local efficiency",
                        "Hemisphere": "Right",
                        "Density (k)": "0.25"
                    },
                    "measures": "[t-statistic, p-value]",
                    "outcomes": "[-3.04, 0.01]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 8,
        "total_ground_truth_claims": 8,
        "number_of_matches": 8
    },
    "PMC5464866_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "tissue type": "cancerous tissues",
                        "sample size": "88",
                        "protein": "FXR",
                        "analysis method": "immunohistochemistry",
                        "comparison": "adjacent tissues"
                    },
                    "measures": "[FXR positive, FXR negative]",
                    "outcomes": "[54 (61.4%), 34 (38.6%)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "FXR expression in the cancerous tissues and the adjacent tissues",
                        "group": "Cancerous tissues",
                        "comparison to": "Adjacent tissues",
                        "expression level": "protein level",
                        "method": "immunohistochemistry",
                        "patients": "88",
                        "FXR positive": "54 (61.4%)",
                        "FXR negative": "34 (38.6%)",
                        "statistical significance": "P < 0.05"
                    },
                    "measures": "[FXR Positive, FXR Negative]",
                    "outcomes": "[54 (61.4%), 34 (38.6%)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "tissue type": "adjacent tissues",
                        "sample size": "88",
                        "protein": "FXR",
                        "analysis method": "immunohistochemistry",
                        "comparison": "cancerous tissues"
                    },
                    "measures": "[FXR positive, FXR negative]",
                    "outcomes": "[27 (30.7%), 61 (69.3%)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "FXR expression in the cancerous tissues and the adjacent tissues",
                        "group": "Adjacent tissues",
                        "comparison to": "Cancerous tissues",
                        "expression level": "protein level",
                        "method": "immunohistochemistry",
                        "patients": "88",
                        "FXR positive": "27 (30.7%)",
                        "FXR negative": "61 (69.3%)",
                        "statistical significance": "P < 0.05"
                    },
                    "measures": "[FXR Positive, FXR Negative]",
                    "outcomes": "[27 (30.7%), 61 (69.3%)]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 4,
        "total_ground_truth_claims": 2,
        "number_of_matches": 2
    },
    "PMC5687650_6": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis type": "Univariate analysis",
                        "outcome measure": "Overall survival (OS)",
                        "risk factor": "Gender",
                        "risk factor categories": "Women or Men"
                    },
                    "measures": "[OR (95% CI), P value]",
                    "outcomes": "[0.770 (0.528-1.124), 0.175]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis_type": "univariate",
                        "risk_factor": "gender",
                        "risk_factor_categories": "women or men"
                    },
                    "measures": "[OR, 95% CI, P value]",
                    "outcomes": "[0.770, 0.528-1.124, 0.175]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis type": "Univariate analysis",
                        "outcome measure": "Overall survival (OS)",
                        "risk factor": "Age",
                        "risk factor categories": ">65 years or \u226465years"
                    },
                    "measures": "[OR (95% CI), P value]",
                    "outcomes": "[0.773 (0.537-1.110), 0.163]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis_type": "univariate",
                        "risk_factor": "age",
                        "risk_factor_categories": ">65 years or \u226465years"
                    },
                    "measures": "[OR, 95% CI, P value]",
                    "outcomes": "[0.773, 0.537-1.110, 0.163]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis type": "Univariate analysis",
                        "outcome measure": "Overall survival (OS)",
                        "risk factor": "PLR",
                        "risk factor categories": "high or low"
                    },
                    "measures": "[OR (95% CI), P value]",
                    "outcomes": "[0.922 (0.641-1.325), 0.660]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis_type": "univariate",
                        "risk_factor": "PLR",
                        "risk_factor_categories": "high or low"
                    },
                    "measures": "[OR, 95% CI, P value]",
                    "outcomes": "[0.922, 0.641-1.325, 0.660]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis type": "Univariate analysis",
                        "outcome measure": "Overall survival (OS)",
                        "risk factor": "NLR",
                        "risk factor categories": "high or low"
                    },
                    "measures": "[OR (95% CI), P value]",
                    "outcomes": "[1.007 (0.701-1.448), 0.969]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis_type": "univariate",
                        "risk_factor": "NLR",
                        "risk_factor_categories": "high or low"
                    },
                    "measures": "[OR, 95% CI, P value]",
                    "outcomes": "[1.007, 0.701-1.448, 0.969]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis type": "Univariate analysis",
                        "outcome measure": "Overall survival (OS)",
                        "risk factor": "Post/pre-chemotherapy PLR ratio",
                        "risk factor categories": ">1 or \u22641"
                    },
                    "measures": "[OR (95% CI), P value]",
                    "outcomes": "[1.272 (0.881-1.837), 0.199]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis_type": "univariate",
                        "risk_factor": "post/pre-chemotherapy PLR ratio",
                        "risk_factor_categories": ">1 or \u22641"
                    },
                    "measures": "[OR, 95% CI, P value]",
                    "outcomes": "[1.272, 0.881-1.837, 0.199]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis type": "Univariate analysis",
                        "outcome measure": "Overall survival (OS)",
                        "risk factor": "Post/pre-chemotherapy NLR ratio",
                        "risk factor categories": ">1 or \u22641"
                    },
                    "measures": "[OR (95% CI), P value]",
                    "outcomes": "[1.902 (1.290-2.803), 0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis_type": "univariate",
                        "risk_factor": "post/pre-chemotherapy NLR ratio",
                        "risk_factor_categories": ">1 or \u22641"
                    },
                    "measures": "[OR, 95% CI, P value]",
                    "outcomes": "[1.902, 1.290-2.803, 0.001]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis type": "Multivariate analysis",
                        "outcome measure": "Overall survival (OS)",
                        "risk factor": "Post/pre-chemotherapy NLR ratio",
                        "risk factor categories": ">1 or \u22641"
                    },
                    "measures": "[OR (95% CI), P value]",
                    "outcomes": "[1.902 (1.290-2.803), 0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis_type": "multivariate",
                        "risk_factor": "post/pre-chemotherapy NLR ratio",
                        "risk_factor_categories": ">1 or \u22641"
                    },
                    "measures": "[OR, 95% CI, P value]",
                    "outcomes": "[1.902, 1.290-2.803, 0.001]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 7,
        "total_ground_truth_claims": 7,
        "number_of_matches": 7
    },
    "PMC5641200_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Red blood cells count decreased",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[5, 83]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['83']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Red blood cells count decreased",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Red blood cells count decreased",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['17']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Red blood cells count decreased",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Red blood cells count decreased",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Red blood cells count decreased",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Red blood cells count decreased",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Red blood cells count decreased",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['50']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['50']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['17']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['50']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Leukopenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['25']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['67']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['25']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Neutropenia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['25']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['50']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "AST increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['17']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "AST increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['100']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[4, 67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['67']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['17']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "ALT increase",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['17']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "ALT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['75']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['17']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "GGT increase",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['17']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['17']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['33']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['25']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hypocalcemia",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['25']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['17']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['17']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Hyponatremia",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['25']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Nausea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[3, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['50']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 50]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['50']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Nausea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['25']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Vomiting",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['33']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Vomiting",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['25']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Diarrhea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Diarrhea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Diarrhea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['33']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Diarrhea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Diarrhea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Diarrhea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 1",
                        "dose": "<100 mg",
                        "number of patients": "6",
                        "adverse event": "Diarrhea",
                        "grade": "G3"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[2, 33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Diarrhea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['33']"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Diarrhea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Diarrhea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Diarrhea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G1"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Diarrhea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['5']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Red blood cells count decreased",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Leukopenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Neutropenia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "AST increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['4']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "ALT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "GGT increase",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hypocalcemia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Hyponatremia",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['3']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Nausea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Vomiting",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 2",
                        "Sample Size": "4",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['1']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Diarrhea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 incidence']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Diarrhea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G1 count']",
                    "outcomes": "['0']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Diarrhea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G2 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "treatment": "dasatinib",
                        "adverse event classification": "NCI-CTCAE v4.03",
                        "dose level": "Level 2",
                        "dose": "100 mg",
                        "number of patients": "4",
                        "adverse event": "Diarrhea",
                        "grade": "G2"
                    },
                    "measures": "[number of patients, percentage]",
                    "outcomes": "[1, 25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "AE": "Diarrhea",
                        "Treatment": "Dasatinib",
                        "Dose Level": "Level 1",
                        "Sample Size": "6",
                        "Grading System": "NCI-CTCAE v4.03"
                    },
                    "measures": "['G3 count']",
                    "outcomes": "['2']"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 35,
        "total_ground_truth_claims": 126,
        "number_of_matches": 33
    },
    "PMC5716794_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.694 \u00b1 0.077, 0.582\u20130.791]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.707 \u00b1 0.074, 0.596\u20130.802]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.731 \u00b1 0.070, 0.622\u20130.823]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.751 \u00b1 0.067, 0.643\u20130.840]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.756 \u00b1 0.065, 0.649\u20130.844]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.770 \u00b1 0.062, 0.664\u20130.856]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[62.5%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[82.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.788 \u00b1 0.059, 0.684\u20130.871]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[92.2, 82.7\u201397.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.1%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[66.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[84.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.793 \u00b1 0.058, 0.689\u20130.874]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[93.8, 84.8\u201398.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.3%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[71.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[85.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.800 \u00b1 0.056, 0.697\u20130.881]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[95.3, 86.9\u201399.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[76.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "55 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.687 \u00b1 0.079",
                        "AUC CI": "0.575\u22120.785",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.4%",
                        "NPV": "56.3%",
                        "accuracy": "80.5%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.687, 89.1, 50.0, 86.4, 56.3, 80.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.694 \u00b1 0.077, 0.582\u20130.791]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.707 \u00b1 0.074, 0.596\u20130.802]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.731 \u00b1 0.070, 0.622\u20130.823]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.751 \u00b1 0.067, 0.643\u20130.840]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.756 \u00b1 0.065, 0.649\u20130.844]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.770 \u00b1 0.062, 0.664\u20130.856]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[62.5%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[82.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.788 \u00b1 0.059, 0.684\u20130.871]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[92.2, 82.7\u201397.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.1%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[66.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[84.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.793 \u00b1 0.058, 0.689\u20130.874]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[93.8, 84.8\u201398.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.3%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[71.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[85.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.800 \u00b1 0.056, 0.697\u20130.881]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[95.3, 86.9\u201399.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[76.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.694 \u00b1 0.077",
                        "AUC CI": "0.582\u22120.791",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.694, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.694 \u00b1 0.077, 0.582\u20130.791]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.707 \u00b1 0.074, 0.596\u20130.802]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.731 \u00b1 0.070, 0.622\u20130.823]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.751 \u00b1 0.067, 0.643\u20130.840]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.756 \u00b1 0.065, 0.649\u20130.844]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.770 \u00b1 0.062, 0.664\u20130.856]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[62.5%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[82.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.788 \u00b1 0.059, 0.684\u20130.871]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[92.2, 82.7\u201397.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.1%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[66.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[84.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.793 \u00b1 0.058, 0.689\u20130.874]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[93.8, 84.8\u201398.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.3%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[71.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[85.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.800 \u00b1 0.056, 0.697\u20130.881]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[95.3, 86.9\u201399.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[76.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.707 \u00b1 0.074",
                        "AUC CI": "0.596\u22120.802",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.707, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.694 \u00b1 0.077, 0.582\u20130.791]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.707 \u00b1 0.074, 0.596\u20130.802]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.731 \u00b1 0.070, 0.622\u20130.823]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.751 \u00b1 0.067, 0.643\u20130.840]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.756 \u00b1 0.065, 0.649\u20130.844]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.770 \u00b1 0.062, 0.664\u20130.856]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[62.5%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[82.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.788 \u00b1 0.059, 0.684\u20130.871]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[92.2, 82.7\u201397.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.1%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[66.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[84.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.793 \u00b1 0.058, 0.689\u20130.874]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[93.8, 84.8\u201398.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.3%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[71.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[85.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.800 \u00b1 0.056, 0.697\u20130.881]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[95.3, 86.9\u201399.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[76.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.731 \u00b1 0.070",
                        "AUC CI": "0.622\u22120.823",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "50.0%",
                        "specificity CI": "26.0\u221274.0%",
                        "PPV": "86.6%",
                        "NPV": "59.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.731, 90.6, 50.0, 86.6, 59.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.694 \u00b1 0.077, 0.582\u20130.791]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.707 \u00b1 0.074, 0.596\u20130.802]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.731 \u00b1 0.070, 0.622\u20130.823]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.751 \u00b1 0.067, 0.643\u20130.840]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.756 \u00b1 0.065, 0.649\u20130.844]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.770 \u00b1 0.062, 0.664\u20130.856]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[62.5%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[82.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.788 \u00b1 0.059, 0.684\u20130.871]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[92.2, 82.7\u201397.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.1%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[66.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[84.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.793 \u00b1 0.058, 0.689\u20130.874]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[93.8, 84.8\u201398.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.3%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[71.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[85.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.800 \u00b1 0.056, 0.697\u20130.881]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[95.3, 86.9\u201399.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[76.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.751 \u00b1 0.067",
                        "AUC CI": "0.643\u22120.840",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.751, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.694 \u00b1 0.077, 0.582\u20130.791]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.707 \u00b1 0.074, 0.596\u20130.802]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.731 \u00b1 0.070, 0.622\u20130.823]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.751 \u00b1 0.067, 0.643\u20130.840]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.756 \u00b1 0.065, 0.649\u20130.844]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.770 \u00b1 0.062, 0.664\u20130.856]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[62.5%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[82.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.788 \u00b1 0.059, 0.684\u20130.871]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[92.2, 82.7\u201397.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.1%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[66.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[84.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.793 \u00b1 0.058, 0.689\u20130.874]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[93.8, 84.8\u201398.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.3%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[71.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[85.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.800 \u00b1 0.056, 0.697\u20130.881]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[95.3, 86.9\u201399.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[76.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.756 \u00b1 0.065",
                        "AUC CI": "0.649\u22120.844",
                        "sensitivity": "89.1%",
                        "sensitivity CI": "78.8\u221295.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.7%",
                        "NPV": "58.9%",
                        "accuracy": "81.7%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.756, 89.1, 55.6, 87.7, 58.9, 81.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.694 \u00b1 0.077, 0.582\u20130.791]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.707 \u00b1 0.074, 0.596\u20130.802]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.731 \u00b1 0.070, 0.622\u20130.823]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.751 \u00b1 0.067, 0.643\u20130.840]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.756 \u00b1 0.065, 0.649\u20130.844]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.770 \u00b1 0.062, 0.664\u20130.856]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[62.5%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[82.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.788 \u00b1 0.059, 0.684\u20130.871]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[92.2, 82.7\u201397.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.1%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[66.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[84.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.793 \u00b1 0.058, 0.689\u20130.874]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[93.8, 84.8\u201398.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.3%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[71.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[85.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.800 \u00b1 0.056, 0.697\u20130.881]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[95.3, 86.9\u201399.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[76.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.770 \u00b1 0.062",
                        "AUC CI": "0.664\u22120.856",
                        "sensitivity": "90.6%",
                        "sensitivity CI": "80.7\u221296.5%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "87.9%",
                        "NPV": "62.5%",
                        "accuracy": "82.9%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.770, 90.6, 55.6, 87.9, 62.5, 82.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.694 \u00b1 0.077, 0.582\u20130.791]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.707 \u00b1 0.074, 0.596\u20130.802]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.731 \u00b1 0.070, 0.622\u20130.823]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.751 \u00b1 0.067, 0.643\u20130.840]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.756 \u00b1 0.065, 0.649\u20130.844]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.770 \u00b1 0.062, 0.664\u20130.856]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[62.5%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[82.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.788 \u00b1 0.059, 0.684\u20130.871]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[92.2, 82.7\u201397.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.1%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[66.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[84.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.793 \u00b1 0.058, 0.689\u20130.874]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[93.8, 84.8\u201398.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.3%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[71.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[85.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.800 \u00b1 0.056, 0.697\u20130.881]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[95.3, 86.9\u201399.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[76.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.788 \u00b1 0.059",
                        "AUC CI": "0.684\u22120.871",
                        "sensitivity": "92.2%",
                        "sensitivity CI": "82.7\u221297.4%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.1%",
                        "NPV": "66.7%",
                        "accuracy": "84.2%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.788, 92.2, 55.6, 88.1, 66.7, 84.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.694 \u00b1 0.077, 0.582\u20130.791]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.707 \u00b1 0.074, 0.596\u20130.802]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.731 \u00b1 0.070, 0.622\u20130.823]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.751 \u00b1 0.067, 0.643\u20130.840]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.756 \u00b1 0.065, 0.649\u20130.844]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.770 \u00b1 0.062, 0.664\u20130.856]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[62.5%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[82.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.788 \u00b1 0.059, 0.684\u20130.871]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[92.2, 82.7\u201397.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.1%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[66.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[84.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.793 \u00b1 0.058, 0.689\u20130.874]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[93.8, 84.8\u201398.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.3%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[71.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[85.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.800 \u00b1 0.056, 0.697\u20130.881]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[95.3, 86.9\u201399.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[76.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.793 \u00b1 0.058",
                        "AUC CI": "0.689\u22120.874",
                        "sensitivity": "93.8%",
                        "sensitivity CI": "84.8\u221298.3%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.3%",
                        "NPV": "71.6%",
                        "accuracy": "85.4%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.793, 93.8, 55.6, 88.3, 71.6, 85.4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.694 \u00b1 0.077, 0.582\u20130.791]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "82 mm^2",
                        "optimal cutoff value": "1.72 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.707 \u00b1 0.074, 0.596\u20130.802]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "99 mm^2",
                        "optimal cutoff value": "1.73 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.731 \u00b1 0.070, 0.622\u20130.823]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[50.0, 26.0\u201374.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[59.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "134 mm^2",
                        "optimal cutoff value": "1.74 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.751 \u00b1 0.067, 0.643\u20130.840]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "152 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.756 \u00b1 0.065, 0.649\u20130.844]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[89.1, 78.8\u201395.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[58.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "161 mm^2",
                        "optimal cutoff value": "1.70 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[81.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.770 \u00b1 0.062, 0.664\u20130.856]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[90.6, 80.7\u201396.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[87.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[62.5%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "189 mm^2",
                        "optimal cutoff value": "1.75 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[82.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.788 \u00b1 0.059, 0.684\u20130.871]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[92.2, 82.7\u201397.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.1%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[66.7%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "214 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[84.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.793 \u00b1 0.058, 0.689\u20130.874]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[93.8, 84.8\u201398.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.3%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[71.6%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "223 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[85.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Area under curve (AUC) \u00b1 standard error, 95% CI]",
                    "outcomes": "[0.800 \u00b1 0.056, 0.697\u20130.881]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Sensitivities, 95% CI]",
                    "outcomes": "[95.3, 86.9\u201399.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Specificities, 95% CI]",
                    "outcomes": "[55.6, 30.8\u201378.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Positive predictive value (PPV)]",
                    "outcomes": "[88.4%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Negative predictive value (NPV)]",
                    "outcomes": "[76.9%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s",
                        "AUC": "0.800 \u00b1 0.056",
                        "AUC CI": "0.697\u22120.881",
                        "sensitivity": "95.3%",
                        "sensitivity CI": "86.9\u221299.0%",
                        "specificity": "55.6%",
                        "specificity CI": "30.8\u221278.5%",
                        "PPV": "88.4%",
                        "NPV": "76.9%",
                        "accuracy": "86.6%"
                    },
                    "measures": "[AUC, sensitivity, specificity, PPV, NPV, accuracy]",
                    "outcomes": "[0.800, 95.3, 55.6, 88.4, 76.9, 86.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "ROC analysis",
                        "comparison": "pancreatic adenocarcinoma vs healthy pancreas",
                        "ROI size": "245 mm^2",
                        "optimal cutoff value": "1.79 \u00d7 10^-3 mm^2/s"
                    },
                    "measures": "[Accuracy (ACC)]",
                    "outcomes": "[86.6%]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 10,
        "total_ground_truth_claims": 54,
        "number_of_matches": 0
    },
    "PMC3757392_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "vector": "C595:MUC1",
                        "cell line": "Capan-1",
                        "ICC": "++",
                        "flow cytometry": "40",
                        "confocal microscopy": "++",
                        "Do": "170 kBq"
                    },
                    "measures": "[ICC, flow cytometry, confocal microscopy, Do]",
                    "outcomes": "[++, 40, ++, 170]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "vector": "C595:MUC1",
                        "cell line": "Capan-1"
                    },
                    "measures": "[ICC (immunocytochemistry), flow cytometry, confocal microscopy, Do (kBq)]",
                    "outcomes": "[++, 40, ++, 170]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "vector": "C595:MUC1",
                        "cell line": "Cfpac-1",
                        "ICC": "+++",
                        "flow cytometry": "500",
                        "confocal microscopy": "+++",
                        "Do": "140 kBq"
                    },
                    "measures": "[ICC, flow cytometry, confocal microscopy, Do]",
                    "outcomes": "[+++, 500, +++, 140]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "vector": "C595:MUC1",
                        "cell line": "Cfpac-1"
                    },
                    "measures": "[ICC (immunocytochemistry), flow cytometry, confocal microscopy, Do (kBq)]",
                    "outcomes": "[+++, 500, +++, 140]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "vector": "C595:MUC1",
                        "cell line": "Panc-1",
                        "ICC": "+++",
                        "flow cytometry": "80",
                        "confocal microscopy": "+++",
                        "Do": "160 kBq"
                    },
                    "measures": "[ICC, flow cytometry, confocal microscopy, Do]",
                    "outcomes": "[+++, 80, +++, 160]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "vector": "C595:MUC1",
                        "cell line": "Panc-1"
                    },
                    "measures": "[[ICC (immunocytochemistry), flow cytometry, confocal microscopy, Do (kBq)]",
                    "outcomes": "[+++, 80, +++, 160]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "vector": "394:uPA",
                        "cell line": "Capan-1",
                        "ICC": "++",
                        "flow cytometry": "88",
                        "confocal microscopy": "++",
                        "Do": "190 kBq"
                    },
                    "measures": "[ICC, flow cytometry, confocal microscopy, Do]",
                    "outcomes": "[++, 88, ++, 190]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "vector": "394:uPA",
                        "cell line": "Capan-1"
                    },
                    "measures": "[[ICC (immunocytochemistry), flow cytometry, confocal microscopy, Do (kBq)]",
                    "outcomes": "[++, 88, ++, 190]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "vector": "394:uPA",
                        "cell line": "Cfpac-1",
                        "ICC": "+++",
                        "flow cytometry": "92",
                        "confocal microscopy": "+++",
                        "Do": "130 kBq"
                    },
                    "measures": "[ICC, flow cytometry, confocal microscopy, Do]",
                    "outcomes": "[+++, 92, +++, 130]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "vector": "394:uPA",
                        "cell line": "Cfpac-1"
                    },
                    "measures": "[[ICC (immunocytochemistry), flow cytometry, confocal microscopy, Do (kBq)]",
                    "outcomes": "[+++, 92, +++, 130]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "vector": "394:uPA",
                        "cell line": "Panc-1",
                        "ICC": "+++",
                        "flow cytometry": "91",
                        "confocal microscopy": "+++",
                        "Do": "170 kBq"
                    },
                    "measures": "[ICC, flow cytometry, confocal microscopy, Do]",
                    "outcomes": "[+++, 91, +++, 170]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "vector": "394:uPA",
                        "cell line": "Panc-1"
                    },
                    "measures": "[[ICC (immunocytochemistry), flow cytometry, confocal microscopy, Do (kBq)]",
                    "outcomes": "[+++, 91, +++, 170]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "vector": "2200-2500",
                        "cell line": "all cells",
                        "Do": "2200-2500 kBq"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "vector": "2200-2500",
                        "cell line": "all cells"
                    },
                    "measures": "[Do (kBq)]",
                    "outcomes": "[2200-2500]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 7,
        "total_ground_truth_claims": 7,
        "number_of_matches": 7
    }
}